Physiological monitor gauge panel

Information

  • Patent Grant
  • 10955270
  • Patent Number
    10,955,270
  • Date Filed
    Thursday, September 28, 2017
    7 years ago
  • Date Issued
    Tuesday, March 23, 2021
    3 years ago
Abstract
A physiological monitor gauge panel defines parameters to display on a physiological monitor via corresponding gauges. Gauge faces depict a range of parameter values for each of the parameters. An indicator designates a position on each gauge face corresponding to the current parameter value within the range of parameter values. The indicated position on each of the gauges is at the mid-point of each of the gauge faces when each of the parameters is at a nominal value.
Description
BACKGROUND OF THE INVENTION

Pulse oximetry is a widely accepted noninvasive procedure for measuring the oxygen saturation level of arterial blood, an indicator of a person's oxygen supply. A typical pulse oximetry system utilizes an optical sensor attached to a fingertip to measure the relative volume of oxygenated hemoglobin in pulsatile arterial blood flowing within the fingertip. Oxygen saturation (SpO2), pulse rate and a plethysmograph waveform, which is a visualization of pulsatile blood flow over time, are displayed on a monitor accordingly.


Conventional pulse oximetry assumes that arterial blood is the only pulsatile blood flow in the measurement site. During patient motion, venous blood also moves, which causes errors in conventional pulse oximetry. Advanced pulse oximetry processes the venous blood signal so as to report true arterial oxygen saturation and pulse rate under conditions of patient movement. Advanced pulse oximetry also functions under conditions of low perfusion (small signal amplitude), intense ambient light (artificial or sunlight) and electrosurgical instrument interference, which are scenarios where conventional pulse oximetry tends to fail.


Advanced pulse oximetry is described in at least U.S. Pat. Nos. 6,770,028; 6,658,276; 6,157,850; 6,002,952; 5,769,785 and 5,758,644, which are assigned to Masimo Corporation (“Masimo”) of Irvine, Calif. and are incorporated in their entirety by reference herein. Corresponding low noise optical sensors are disclosed in at least U.S. Pat. Nos. 6,985,764; 6,813,511; 6,792,300; 6,256,523; 6,088,607; 5,782,757 and 5,638,818, which are also assigned to Masimo and are also incorporated in their entirety by reference herein. Advanced pulse oximetry systems including Masimo SET® low noise optical sensors and read through motion pulse oximetry monitors for measuring SpO2, pulse rate (PR) and perfusion index (PI) are available from Masimo. Optical sensors include any of Masimo LNOP®, LNCS®, SofTouch™ and BIue™ adhesive or reusable sensors. Pulse oximetry monitors include any of Masimo Rad-8®, Rad-5®, Rad®-5v or SatShare® monitors.


Advanced blood parameter measurement systems are described in at least U.S. Pat. No. 7,647,083, filed Mar. 1, 2006, titled Multiple Wavelength Sensor Equalization; U.S. Pat. No. 7,729,733, filed Mar. 1, 2006, titled Configurable Physiological Measurement System; U.S. Pat. Pub. No. 2006/0211925, filed Mar. 1, 2006, titled Physiological Parameter Confidence Measure and U.S. Pat. Pub. No. 2006/0238358, filed Mar. 1, 2006, titled Noninvasive Multi-Parameter Patient Monitor, all assigned to Cercacor Laboratories, Inc., Irvine, Calif. (Cercacor) and all incorporated in their entirety by reference herein. Advanced blood parameter measurement systems include Masimo Rainbow® SET, which provides measurements in addition to SpO2, such as total hemoglobin (SpHb™), oxygen content (SpOC™), methemoglobin (SpMet®), carboxyhemoglobin (SpCO®) and PVI®. Advanced blood parameter sensors include Masimo Rainbow® adhesive, ReSposable™ and reusable sensors. Advanced blood parameter monitors include Masimo Radical-7™, Rad87™ and Rad57™, Pronto-7® and Pronto® monitors, all available from Masimo. Such advanced pulse oximeters, low noise sensors and advanced blood parameter systems have gained rapid acceptance in a wide variety of medical applications, including surgical wards, intensive care and neonatal units, general wards, home care, physical training, and virtually all types of monitoring scenarios.


SUMMARY OF THE INVENTION

A physiological monitor gauge panel displays a graphical user interface (GUI) that allows medical care providers to quickly view and immediately and intuitively recognize and assess patient status across multiple parameters. The GUI comprises multiple gauges arranged in a panel. In an embodiment, a face of each gauge is configured as a circular portion. A needle of each gauge rotatably moves across the gauge face so as to indicate a parameter value. A gauge readout integrated with the gauge face also indicates a parameter value. An alarm region is disposed along at least one end of the face so as to indicate a lower alarm limit, an upper alarm limit or both lower and upper alarm limits. The alarm region becomes brightly illuminated when the needle is within the alarm region so as to alert a caregiver of an alarm condition.


In an embodiment, the physiological monitor gauge has a gauge face with generally semi-circular upper and lower edges defining downward-oriented ends and a mid-point between the ends defining an arced peak. Positions along the gauge face correspond to physiological parameter values. An indicator is disposed on the gauge face and is moveable along the gauge face according to a parameter value. The parameter value is displayed as at least one digit underneath the arced peak. The parameter type is specified under the parameter value.


One aspect of a physiological monitor gauge panel has a gauge face with generally semi-circular upper and lower edges. Each edge has downward-oriented ends and a mid-point defining an arced peak. Positions along the gauge face correspond to parameter values. An indicator is disposed on the gauge face and is moveable along the gauge face according to parameter values. At least one digit is displayed underneath the arced peak according to parameter values, and a parameter type is displayed under the at least one digit. In various embodiments, a generally arced color bar is disposed along the gauge face proximate at least one of the ends. The color bar defines an alarm region for parameter values. An arced histogram is disposed above the gauge face upper edge having bins, each of which generally represent parameter values corresponding to bin positions along the gauge face. Bin fills are depicted as relatively dark lines of various lengths coextending with particular ones of the bins. The bin fills each depict the amount of time the indicator persists at a given parameter value associated with a bin position.


Further aspect of a physiological monitor gauge panel are an alarm condition corresponding to the indicator positioned over the color bar. The gauge face changes from a generally neutral color to a red color during the alarm condition. Parameter value digits change from a black color to a white color during the alarm condition, and a background of the parameter value changes to a generally red color. A ghost face represents an unused quarter-circle region proximate one of the gauge face ends. A second generally arced color bar is located proximate the color bar and defines a cautionary region for parameter values. Gauge faces and corresponding indicators, parameter values and parameter types define a panel of parameter gauges. The indicators of each parameter gauge are generally centered at each of the arced peaks of the gauge faces so as to designate generally nominal values for the underlying physiological parameters. The panel displaying one or more significantly off-centered indicators signifies a potentially significant physiological event.


Another aspect of a physiological monitor gauge panel defines parameters to display on a physiological monitor via corresponding gauges. Gauge faces depict a range of parameter values for each of the parameters. An indicator designates a position on each gauge face corresponding to the current parameter value within the range of parameter values. The indicated position on each of the gauges is at the mid-point of each of the gauge faces when each of the parameters is at a nominal value. In various embodiments, gauge faces define a semi-circular range for each parameter. A low-range gauge has a left quarter-circle active face portion and a right quarter-circle inactive face portion. A high-range gauge has a right quarter-circle active face portion and a left quarter-circle inactive face portion. A high/low-range gauge has both a right quarter-circle active face portion and a left quarter-circle active face portion. A color bar designates an alarm region of parameter values. A second color bar designates a cautionary region of parameter values.


Yet another aspect of a physiological monitor gauge is a gauge face for depicting a range of values of a parameter on a physiological monitor. An indicator rotatably moves along the gauge face in response to the parameter so as to designate a current value for the parameter. The gauge face is configured so that the indicator is centered on the gauge face when the parameter current value is a nominal value. In various embodiments, the gauge face has a left-sided active face when the parameter has alarm limits for only low parameter values and a right-sided active face when the parameter has alarm limits for only high parameter values. The gauge face has both a left-sided active face and a right-sided active face when the parameter has alarm limits for both low parameter values and high parameter values. An active histogram is disposed proximate the active face for indicating the amount of time the indicator persists at a given parameter value. A virtual sliding knob sets the alarm limits along the gauge face.





DESCRIPTION OF THE DRAWINGS


FIG. 1 is a physiological monitor gauge panel illustration presenting nominal values for each parameter and dual (red and yellow zone) alarm limits;



FIG. 2 is a physiological monitor gauge panel illustration presenting less than nominal values for each parameter;



FIG. 3 is a physiological monitor gauge panel illustration presenting an alarm condition for a particular parameter;



FIG. 4 is a parameter gauge illustration presenting an active histogram;



FIG. 5 is a parameter gauge illustration presenting an alarm limit editor;



FIG. 6 is a parameter gauge illustration presenting a 3-dimensional edge;



FIG. 7 is a parameter gauge illustration presenting a visible needle indicator;



FIG. 8 is a quarter-circle parameter gauge illustration; and



FIG. 9 is a parameter gauge illustration presenting single (red zone) alarm limits.



FIG. 10 illustrates a block diagram of an exemplary embodiment of a patient monitoring system including a sensor and a multi-parameter patient monitor.



FIG. 11 illustrates a top elevation view of an exemplary handheld noninvasive multi-parameter patient monitor capable of displaying at least HbCO, such as, for example, the patient monitor of FIG. 10.



FIG. 12 illustrates an exemplary display of the patient monitor of FIG. 11.



FIG. 13 illustrates the display of FIG. 12 showing measured values of SpO2, BPM, perfusion, and type of sensor according to an exemplary embodiment of the patient monitor of FIG. 10.



FIG. 14 illustrates the display of FIG. 12 showing measured values of HbCO, perfusion, and type of sensor according to an exemplary embodiment of the patient monitor of FIG. 10.



FIG. 15 illustrates the display of FIG. 12 showing measured values of SpO2, HbCO, BPM, perfusion, and type of sensor, according to an exemplary embodiment of the patient monitor of FIG. 10.



FIG. 16 illustrates a top elevation view of an exemplary handheld noninvasive multi-parameter patient monitor capable of displaying at least HbCO and HbMet, such as, for example, the patient monitor of FIG. 10.



FIG. 17 illustrates an exemplary display of the patient monitor of FIG. 16.



FIG. 18 illustrates the display of FIG. 17 showing measured values of SpO2, BPM, HbCO, HbMet, and type of sensor according to an exemplary embodiment of the patient monitor of FIG. 10.



FIG. 19 illustrates the display of FIG. 17 showing measured values of HbCO, HbMet, and type of sensor according to an exemplary embodiment of the patient monitor of FIG. 10.



FIG. 20A illustrates a perspective view of an exemplary noninvasive multi-parameter patient monitor such as, for example, the patient monitor of FIG. 10.



FIGS. 20B-20H illustrate display screens of the patient monitor of FIG. 20A.





DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS


FIG. 1 illustrates a physiological monitor gauge panel 100 embodiment configured as a GUI (graphical user interface) presented on a monitor display. The gauge panel 100 is depicted as displaying nominal values for each parameter, as described below. Advantageously, a GUI gauge panel presentation of physiological parameters allows medical care providers to quickly view and immediately and intuitively recognize and assess patient status across multiple parameters. Indeed, a familiarity with reading of electrical/mechanical needle gauges is acquired over a lifetime exposure to speedometers, thermometers, tachometers and fuel-level indicators, to name a few.


An exemplar gauge panel configuration displays three half-circle gauges including a SpO2 (oxygen saturation) gauge 101, a SpHb (total hemoglobin) gauge 102 and a SpMet (methemoglobin) gauge 103. Each gauge has a semi-circular face 110 and a parameter value indicator 120 that rotatably travels along each face 110. In particular, each indicator 120 is a visible tip terminating an apparent (unseen) needle that extends from, and rotatably pivots around, a gauge center. See, e.g., FIG. 7, below, illustrating visible needle. The indicator 120 position on the face 110 matches the value of a digital parameter readout 140 of the indicated parameter value. Advantageously, each gauge 101, 102, 103 is configured so that the indicator 120 is at the face mid-point, i.e. straight up as depicted, when the parameter is at a nominal value. In this manner, a caregiver will immediately recognize a patient having one or more abnormal readings and the degree of abnormality across multiple parameters.


As shown in FIG. 1, a low-range-alarm gauge 101 is configured for parameters having alarm limits for only low parameter values. A high-range-alarm gauge 103 is configured for parameters having alarm limits for only high parameter values. A high/low-range-alarm gauge 102 is configured for parameters having alarm limits for both low and high parameter values.


Also shown in FIG. 1, a low-range-alarm gauge 101 embodiment is configured with a left quarter-circle active face 112 depicting a possible range of parameter values. A right quarter-circle inactive face 114 is unused. In an embodiment, the inactive face is depicted as a ghost face, e.g. with a thin or light outline, as shown. In other embodiments, the inactive face is not shown, i.e. the gauge 101 has a quarter-circle face, as described with respect to FIG. 8, below. An alarm region is designated by a curved color bar 150 proximate a low-value range 112 of the face 110. A numerical indicator 152 indicates the maximum value of the alarm region. In an embodiment, the color bar 150 is red. In an embodiment, a second color bar 170 indicates a cautionary region. In an embodiment, the second color bar 170 is yellow.


Further shown in FIG. 1, a high-range-alarm gauge 103 embodiment is configured with a right quarter-circle active face 114 depicting a possible range of parameter values. A left quarter-circle inactive face 112 is unused. In an embodiment, the inactive face is depicted as a ghost face 190 as shown. In other embodiments, the inactive face is not shown. An alarm region is designated by a curved color bar 160 (e.g. red) proximate a high-value range 114 of the face 110. A numerical indicator 162 indicates the minimum value of the alarm region. In an embodiment, a second color bar 180 (e.g. yellow) indicates a cautionary region.


Additionally shown in FIG. 1, a low/high-range-alarm gauge 102 embodiment is configured with a semi-circle active face 112, 114 depicting a possible range of parameter values. A left quarter-circle active face 112 illustrates high range values and a right quarter-circle active face 114 illustrates low range values. Alarm regions are designated by a curved (red) color bars 150, 160 at the high and low parameter ranges, respectively. Numerical indicators 152,162 indicate the alarm onset regions. In an embodiment, a second (yellow) color bars 170, 180 indicates cautionary regions. In an embodiment, the parameter value indicator 120 is a brightly illuminated white.



FIG. 2 illustrates a physiological monitor gauge panel 200 presenting less than nominal values for each parameter. In particular, each gauge 101, 102, 103 has an indicator located away from a vertical (straight-up) position, as compared with the panel 100 (FIG. 1), described above. Advantageously, the off-vertical indicators 120 immediate signal a caregiver of one or more abnormal readings and the degree of abnormality across multiple parameters.



FIG. 3 illustrates a physiological monitor gauge panel 300 presenting an SpHb parameter gauge 101 that indicates an alarm condition. In particular, the gauge indicator 120 and readout 140 indicate SpHb has dropped below a listed limit of 7. In an embodiment, the alarm condition is advantageously indicated by the red color bar 150 changing to a brightest red illumination and also glowing red, the numerical value 140 changing to solid white, the color of the face 110 border changing to red and the readout background 145 changing to a bright red illumination and also having a red glow. Advantageously, these various visual cues allow a caregiver to quickly recognize the alarming parameter and the severity of the underlying physiological condition of the patient.



FIG. 4 illustrates a parameter gauge 400 presenting an active histogram 410. The histogram has bins 412 evenly distributed around the outer edge of the gauge face 110. The bins 412 are depicted as relatively light, radially extending lines, all of the same length. Bin fill 414 are depicted as relatively dark lines of various lengths coextending with particular ones of the bins 412. The histogram 410 advantageously depicts the amount of time the indicator 120 persists at a given parameter value corresponding to a bin position. The greater amount of time the indicator 120 persists at a given parameter value, the further the histogram fill corresponding to that bin extends from the inner edge to the outer edge of the histogram scale. In an embodiment, the histogram 410 extends the full travel range of the indicator 120.



FIG. 5 illustrates a parameter gauge 500 presenting an alarm limit editor. When a user touches an alarm limit number, e.g. 152 (FIG. 1), the alarm limit number and histogram (if enabled) fades out. These are replaced by a dual knob slider 501. The slider 501 has a decreasing value (relative to the center) left side 510 and an increasing value (relative to the center) right side 520. Accordingly, the slider 501 has a corresponding left side knob 512, left side label 514, right side knob 522 and right side label 524. A user can slide each knob 512, 522 with a finger along a slider carve 550. Each label 514, 524 will track with the corresponding knob 512, 522 position, and the value depicted on each label 514, 524 will update as the corresponding knob is moved. The color (red) alarm bars also track and move with the knobs 512, 522. The between-the-knobs carve portion 555 is also colored (black) so as to help identify the knob positions. Half gauges, such as 101 (FIG. 1) and 103 (FIG. 1) having a single (decreasing or increasing) range have a single knob and label accordingly.



FIGS. 6-9 each illustrate various other parameter gauge embodiments. FIG. 6 illustrates a parameter gauge 600 having a gauge face 110 with an apparent edge 610 so as to appear three-dimensional. FIG. 7 illustrates a parameter gauge 700 with an indicator 120 that sits atop a visible needle 125. The needle 125 and corresponding indicator 120 rotate about a gauge center 113. FIG. 8 illustrates a quarter-circle parameter gauge 800, i.e. a gauge without a ghost face 190 (FIG. 1) to indicate an inactive gauge portion. FIG. 9 illustrates a parameter gauge 900 having only red zone alarm regions 150, 160, i.e. without cautionary yellow zone regions 170, 180 (FIG. 1).


A physiological monitor gauge panel has been disclosed in detail in connection with various embodiments. These embodiments are disclosed by way of examples only and are not to be construed as limiting the scope of the claims that follow. One of ordinary skill in the art will appreciate many variations and modifications.


Embodiments of the present disclosure include a portable or other multi-parameter patient monitor capable of determining multiple physiological parameters from one or more signals output from one or more light sensitive detectors capable of detecting light attenuated by body tissue carrying pulsing blood. For example, in an embodiment, the monitor advantageously and accurately determines a wide variety of physiological parameters or other calculations as discussed above.


In an embodiment, the display of patient monitor advantageously includes a plurality of display modes enabling more parameter data to be displayed than the available physical display real estate. For example, the patient monitor may include one or more user input keys capable of toggling through measurement data. In an embodiment, the displays include mode indicators providing caregivers easily identifiable visual queues, such as LED's, text, icons, or other indicia providing readily identifiable queues as to which parameter is being displayed. In an embodiment, the display may shift, may be parameter color-coded, or the like to further ensure quick comprehension of which measured parameter is the displayed parameter. For example, in an embodiment, the monitor displays SpO2 in white, pulse rate (BPM) in green, HbCO in orange, and HbMet in blue when the respective measured parameter is within a “normal” range.


In an embodiment, the patient monitor provides an indication that the caregiver should change display modes to view more critical or time sensitive measured parameters, specific caregiver selected parameters, or the like. For example, the patient monitor may advantageously sound audio or visual alarms that alert the caregiver to particular one or more of worsening parameters, parameters changing in a predetermined pattern or rate, parameters stabilizing below user defined or safe thresholds, caregiver selected parameters, or the like. The monitor may also use alerts that provide audio or visual indications of the severity of the condition, severity of the change, or the like. In alternative embodiments, the patient monitor may automatically change display modes when a particular parameter crosses one or more thresholds. For example, a patient monitor may be displaying a first parameter, such as a plethysmograph, and upon determining measurements indicating that HBMet is trending toward an alarm condition, the monitor may automatically switch from displaying the first parameter to the alarming parameter, or in this case, a trend of the alarming parameter.


In an embodiment, a switch is provided to allow a user to switch displays to view an alarming measurement. In an embodiment, during an alarm condition, a parameter display may switch to a trend graph in the same or different color, line weight, flash, flash rate, intensity, size, or the like.


The patient monitor may also include one or more displays capable of displaying trend data for any one or more of the monitored or derived patient parameters. For example, the trend data may be displayed in graph form, may include multiple trend lines, each representing a different monitored or derived patient parameter. Moreover, each trend line may be color-coded to facilitate quick comprehension of which trend line represents which measured parameter. However, an artisan will recognize from the disclosure herein a large number of identification techniques including color-coding, identifying text, or the like. Additionally, user input may toggle displayed trend data, may select which parameters to display simultaneously, or the like.


In an embodiment, the patient monitor includes an audible or visual indication of a type of sensor communicating with the monitor. For example, the patient monitor may provide a particular audio or visual indication, such as a beep, LED activation, graphic activation, text messages, voice messages, or the like, to indicate communication with or connection to an approved sensor, patient cable, combination, or the like. In an embodiment, the indication may change based on the manufacturer, type of sensor recognized or not recognized, type of patient, type of physiological parameters measurable with the attached sensor, or the like. Additional embodiments include an indication of perfusion in the tissue of the measurement site and an indication of the confidence the signal processing has in its output measurements or input signal quality.


To facilitate an understanding of the disclosure, the remainder of the description references exemplary embodiments illustrated in the drawings. Moreover, in this application, reference is made to many blood parameters. Some references that have common shorthand designations are referenced through such shorthand designations. For example, as used herein, HbCO designates carboxyhemoglobin, HbMet designates methemoglobin, and Hbt designates total hemoglobin. Other shorthand designations such as COHb, MetHb, and tHb are also common in the art for these same constituents. These constituents are generally reported herein in terms of a percentage, often referred to as saturation, relative concentration or fractional saturation. Total hemoglobin is generally reported as a concentration in g/dL. The use of the particular shorthand designators presented in this application does not restrict the term to any particular manner in which the designated constituent is reported.



FIG. 10 illustrates a block diagram of an exemplary embodiment of a patient monitoring system 1100. As shown in FIG. 10, the system 1100 includes a patient monitor 1102 comprising a processing board 1104 and a host instrument 1108. The processing board 1104 communicates with a sensor 1106 to receive one or more intensity signal(s) indicative of one or more parameters of tissue of a patient. The processing board 1104 also communicates with a host instrument 1108 to display determined values calculated using the one or more intensity signals. According to an embodiment, the board 1104 comprises processing circuitry arranged on one or more printed circuit boards capable of installation into the monitor 1102, or capable of being distributed as some or all of one or more OEM components for a wide variety of host instruments monitoring a wide variety of patient information. In an embodiment, the processing board 1102 comprises a sensor interface 1110, a digital signal processor and signal extractor (“DSP” or “processor”) 1112, and an instrument manager 1114. In general, the sensor interface 1110 converts digital control signals into analog drive signals capable of driving sensor emitters, and converts composite analog intensity signal(s) from light sensitive detectors into digital data.


In an embodiment, the sensor interface 1110 manages communication with external computing devices. For example, in an embodiment, a multipurpose sensor port (or input/output port) is capable of connecting to the sensor 1106 or alternatively connecting to a computing device, such as a personal computer, a PDA, additional monitoring equipment or networks, or the like. When connected to the computing device, the processing board 1104 may upload various stored data for, for example, off-line analysis and diagnosis. The stored data may comprise trend data for any one or more of the measured parameter data, plethysmograph waveform data acoustic sound waveform, or the like. Moreover, the processing board 1104 may advantageously download from the computing device various upgrades or executable programs, may perform diagnosis on the hardware or software of the monitor 1102. In addition, the processing board 1104 may advantageously be used to view and examine patient data, including raw data, at or away from a monitoring site, through data uploads/downloads, or network connections, combinations, or the like, such as for customer support purposes including software maintenance, customer technical support, and the like. Upgradable sensor ports are disclosed in copending U.S. application Ser. No. 10/898,680, filed on Jul. 23, 2004, titled “Multipurpose Sensor Port”.


As shown in FIG. 10, the digital data is output to the DSP 1112. According to an embodiment, the DSP 1112 comprises a processing device based on the Super Harvard ARChitecture (“SHARC”), such as those commercially available from Analog Devices. However, a skilled artisan will recognize from the disclosure herein that the DSP 1112 can comprise a wide variety of data and/or signal processors capable of executing programs for determining physiological parameters from input data. In particular, the DSP 1112 includes program instructions capable of receiving multiple channels of data related to one or more intensity signals representative of the absorption (from transmissive or reflective sensor systems) of a plurality of wavelengths of emitted light by body tissue. In an embodiment, the DSP 1112 accepts data related to the absorption of eight (8) wavelengths of light, although an artisan will recognize from the disclosure herein that the data can be related to the absorption of two (2) to sixteen (16) or more wavelengths.



FIG. 10 also shows the processing board 1104 including the instrument manager 1114. According to an embodiment, the instrument manager 1114 may comprise one or more microcontrollers controlling system management, including, for example, communications of calculated parameter data and the like to the host instrument 1108. The instrument manager 1114 may also act as a watchdog circuit by, for example, monitoring the activity of the DSP 1112 and resetting it when appropriate.


The sensor 1106 may comprise a reusable clip-type sensor, a disposable adhesive-type sensor, a combination sensor having reusable and disposable components, or the like. Moreover, an artisan will recognize from the disclosure herein that the sensor 1106 can also comprise mechanical structures, adhesive or other tape structures, Velcro wraps or combination structures specialized for the type of patient, type of monitoring, type of monitor, or the like. In an embodiment, the sensor 1106 provides data to the board 1104 and vice versa through, for example, a patient cable. An artisan will also recognize from the disclosure herein that such communication can be wireless, over public or private networks or computing systems or devices, or the like.


As shown in FIG. 10, the sensor 1106 includes a plurality of emitters 1116 irradiating the body tissue 1118 with differing wavelengths of light, and one or more detectors 1120 capable of detecting the light after attenuation by the tissue 1118. In an embodiment, the emitters 1116 comprise a matrix of eight (8) emission devices mounted on a flexible substrate, the emission devices being capable of emitting eight (8) differing wavelengths of light. In other embodiments, the emitters 1116 may comprise twelve (12) or sixteen (16) emitters, although other numbers of emitters are contemplated, including two (2) or more emitters. As shown in FIG. 10, the sensor 1106 may include other electrical components such as, for example, a memory device 1122 comprising an EPROM, EEPROM, ROM, RAM, microcontroller, combinations of the same, or the like. In an embodiment, other sensor components may include a temperature determination device 1123 or other mechanisms for, for example, determining real-time emission wavelengths of the emitters 1116.


The memory 1122 may advantageous store some or all of a wide variety data and information, including, for example, information on the type or operation of the sensor 1106; type or identification of sensor buyer or distributor or groups of buyer or distributors, sensor manufacturer information, sensor characteristics including the number of emitting devices, the number of emission wavelengths, data relating to emission centroids, data relating to a change in emission characteristics based on varying temperature, history of the sensor temperature, current, or voltage, emitter specifications, emitter drive requirements, demodulation data, calculation mode data, the parameters for which the sensor is capable of supplying sufficient measurement data (e.g., HpCO, HpMet, HbT, or the like), calibration or parameter coefficient data, software such as scripts, executable code, or the like, sensor electronic elements, whether the sensor is a disposable, reusable, multi-site, partially reusable, partially disposable sensor, whether it is an adhesive or non-adhesive sensor, whether the sensor is a reflectance, transmittance, or transreflectance sensor, whether the sensor is a finger, hand, foot, forehead, or ear sensor, whether the sensor is a stereo sensor or a two-headed sensor, sensor life data indicating whether some or all sensor components have expired and should be replaced, encryption information, keys, indexes to keys or hash functions, or the like, monitor or algorithm upgrade instructions or data, some or all of parameter equations, information about the patient, age, sex, medications, and other information that may be useful for the accuracy or alarm settings and sensitivities, trend history, alarm history, or the like. In an embodiment, the monitor may advantageously store data on the memory device, including, for example, measured trending data for any number of parameters for any number of patients, or the like, sensor use or expiration calculations, sensor history, or the like.



FIG. 10 also shows the patient monitor 1102 including the host instrument 1108. In an embodiment, the host instrument 1108 communicates with the board 1104 to receive signals indicative of the physiological parameter information calculated by the DSP 1112. The host instrument 1108 preferably includes one or more display devices 1124 capable of displaying indicia representative of the calculated physiological parameters of the tissue 1118 at the measurement site. In an embodiment, the host instrument 1108 may advantageously comprise a handheld housing capable of displaying one or more of a pulse rate, plethysmograph data, perfusion quality such as a perfusion quality index (“PI™”), signal or measurement quality (“SQ”), values of blood constituents in body tissue, including for example, SpO2, HbCO, HbMet, Hbt, or the like. In other embodiments, the host instrument 1108 is capable of displaying values for one or more of Hbt, Hb, blood glucose, bilirubin, or the like. The host instrument 1108 may be capable of storing or displaying historical or trending data related to one or more of the measured values, combinations of the measured values, plethysmograph data, or the like. The host instrument 1108 also includes an audio indicator 1126 and user input device 1128, such as, for example, a keypad, touch screen, pointing device, voice recognition device, or the like.


In still additional embodiments, the host instrument 1108 includes audio or visual alarms that alert caregivers that one or more physiological parameters are falling below predetermined safe thresholds. The host instrument 1108 may include indications of the confidence a caregiver should have in the displayed data. In a further embodiment, the host instrument 1108 may advantageously include circuitry capable of determining the expiration or overuse of components of the sensor 1106, including, for example, reusable elements, disposable elements, or combinations of the same.


Although described in terms of certain embodiments, other embodiments or combination of embodiments will be apparent to those of ordinary skill in the art from the disclosure herein. For example, the monitor 1102 may comprise one or more monitoring systems monitoring parameters, such as, for example, vital signs, blood pressure, ECG or EKG, respiration, glucose, bilirubin, or the like. Such systems may combine other information with intensity-derived information to influence diagnosis or device operation. Moreover, the monitor 1102 may advantageously include an audio system, preferably comprising a high quality audio processor and high quality speakers to provide for voiced alarms, messaging, or the like. In an embodiment, the monitor 1102 may advantageously include an audio out jack, conventional audio jacks, headphone jacks, or the like, such that any of the display information disclosed herein may be audiblized for a listener. For example, the monitor 1102 may include an audible transducer input (such as a microphone, piezoelectric sensor, or the like) for collecting one or more of heart sounds, lung sounds, trachea sounds, or other body sounds and such sounds may be reproduced through the audio system and output from the monitor 1102. Also, wired or wireless communications (such as Bluetooth or WiFi, including IEEE 801.11a, b, or g), mobile communications, combinations of the same, or the like, may be used to transmit the audio output to other audio transducers separate from the monitor 1102.


For example, patterns or changes in the continuous noninvasive monitoring of intensity-derived information may cause the activation of other vital sign measurement devices, such as, for example, blood pressure cuffs.



FIG. 11 illustrates a perspective view of an exemplary handheld noninvasive multi-parameter patient monitor 1200, such as, for example, the patient monitor 1102 of FIG. 11. Patient monitors 1200 exhibiting combinations of many of the features described herein are advantageously commercially available from Masimo under the brand name “Rad 57c.” As shown in FIG. 10, the monitor 1200 includes a patient cable connector 1202 capable of mechanical mating with a patient cable to establish communication between the board 1104 and the sensor 1106. In an embodiment, the connector 1202 comprises a multipurpose cable connector such as that disclosed in U.S. application Ser. No. 10/898,680, titled “Multipurpose Sensor Port,” disclosing communication between the board 1104 and an external computing device.


The monitor 1200 also comprises a HbCO indicator 1204 advantageously providing a visual queue that a HbCO capable sensor is properly connected through the connector 1202. For example, the HbCO indicator 1204 may advantageously activate when a sensor is connected that communicates sufficient information to determine HbCO, such as, for example, a sensor capable of emitting sufficient different wavelengths of light, a sensor storing sufficient data on the memory 1122, a sensor having appropriate encryption data or key, combinations of the same, or the like. For example, in an embodiment, the processor 1112 may receive information from a memory 1122 indicating a number of available LED wavelengths for the attached sensor. Based on the number of wavelengths, or other information stored on the memory 1122, the processor 1112 may determine whether an HbCO-ready sensor has been attached to the monitor 1200. An artisan will also recognize from the disclosure herein that the HbCO indicator 1204 may advantageously comprise a HbMet indicator, Hbt indicator, or the like, which activates to a predetermined color associated with a parameter, or any color, or deactivates the same, to convey a type of attached sensor. Moreover, the artisan will recognize from the disclosure herein other parameters that may use other sensor components and the monitor 1200 may include indicators capable of indicating communication with those types of sensors.


In an embodiment, the monitor 1200 may also audibly indicate the type of sensor connected. For example, the monitor 1200 may emit predetermined number or frequency of beeps associated with recognition of a particular sensor, a particular manufacturer, failure to recognize the sensor, or the like. Moreover, the sensor type may be indicative of the componentry, such as, for example, whether the sensor produces sufficient data for the determination of HbCO, HbMet, Hbt and SpO2, SpO2 only, SpO2 and HbMet, any combination of the foregoing or other parameters, or the like. Additionally, the sensor type may be indicative of specific sensors designed for a type of patient, type of patient tissue, or the like. In other embodiments, the monitor 1200 may announce the type of connector through speaker 1236.


An artisan will also recognize from the disclosure herein that other mechanical (such as keys), electrical, or combination devices may inform the monitor 1200 of the type of attached sensor. In an embodiment, the processor 1112 also may select to drive less emitters that are currently available, such as, for example, in the presence of low noise and when power consumption is an issue.


The monitor 1200 also comprises a multi-mode display 1206 capable of displaying, for example, measurements of SpO2 and HbCO (or alternatively, HbMet). In an embodiment, the display 1206 has insufficient space or display real estate to display the many parameters capable of being measured by the monitor 1200. Thus, the multi-mode display 1206 may advantageously cycle through two or more measured parameters in an area common to both parameters even when shifted. In such embodiments, the monitor 1200 may also advantageously include parameter indicators 1208, 1210, providing additional visual queues as to which parameter is currently displayed. In an embodiment, the display may also cycle colors, flash rates, or other audio or visual queues providing readily identifiable information as to which measured parameter is displayed. For example, when the multi-mode display 1206 displays measured values of SpO2 that are normal, the numbers may advantageously appear in green, while normal measured values of HbCO may advantageously appear in orange, and normal measured values of HbMet may appear in blue. Moreover, in an embodiment, the display 1206 flashes at a predefined rate when searching for saturation and at another predefined rate when a signal quality is below a predetermined threshold.


The monitor 1200 also comprises a HbCO bar 1212 where in an embodiment a plurality of LED's activate from a bottom toward a top such that the bar “fills” to a level proportional to the measured value. For example, the bar 1212 is lowest when the dangers from carbon monoxide poisoning are the least, and highest when the dangers are the greatest. The bar 1212 includes indicia 1214 that provide an indication of the severity of carbon monoxide saturation in a patient's blood. As shown in FIG. 11, the bar 1212 and the indicia 1214 continuously indicate the concentration of HbCO in about 5% increments. The indicia 1214 indicate a measurement of HbCO saturation percentage between about 0 and about 50% with a granularity of about 5%. However, an artisan will also recognize from the disclosure herein a wide variety of ranges and granularities could be used, the indicia 1214 could be electronically displayed in order to straightforwardly increase or decrease resolution, or the like. For example, HbCO may advantageously be displayed with greater resolution than ±about %5 in a lower portion of the scale. For example, an HbCO bar may advantageously include a scale of about <3%, about 6%, about 9%, about 12%, about 15%, about 20%, about 25%, about 30%, about 35%, and about >40%.


As is known in the art, carbon monoxide in the blood can lead to serious medical issues. For example and depending upon the particular physiology of a patient, about 10% carbon monoxide saturation can lead to headaches, about 20% can lead to throbbing headaches, or dyspnea on exertion, about 30% can lead to impaired judgment, nausea, dizziness and/or vomiting, visual disturbance, or fatigue, about 40% can lead to confusion and syncope, and about 50% and above can lead to comas, seizures, respiratory failure and even death.


In an embodiment, the bar 1212 is the same or similar color as the multi-mode display 1206 when displaying HbCO. In other embodiments, the bar 1212 is lowest and green when the dangers from carbon monoxide poisoning are the least, and highest and red when the dangers are the greatest. In an embodiment, as HbCO increases, the entire bar 1212 may advantageously change color, such as, for example, from green to red, to provide a clear indication of deepening severity of the condition. In other embodiments, the bar 1212 may advantageously blink or flash, an audio alarm may beep or provide a continuation or rise in pitch or volume, or the like to alert a caregiver of deepening severity. Moreover, straightforward to complex alarm rules may be implemented to reduce false alarms based on, for example, knowledge of the physiological limitations on the rate of change in HbCO or the like.


Additionally, the monitor 1200 may be capable of storing and outputting historical parameter data, display trend traces or data, or the like. Although the foregoing bar 1212 has been described in terms of certain preferred embodiments, other embodiments will be apparent to those of ordinary skill in the art from the disclosure herein.



FIG. 11 also shows the monitor 1200 including a pulse display 1216 displaying measured pulse rate in beats per minute (“BPM”). In an embodiment, the display 1212 flashes when searching for a pulse. The pulse display 1216 advantageously displays measured pulse rates from about zero (0) to about two hundred and forty (240) BPM. Moreover, when the measured pulse rates are considered normal, the pulse display 1216 is advantageously green. Similar to other displays associated with the monitor 1200, the pulse display 1216 may employ a variety of color changes, audio alarms, or combinations of the same to indicate measured BPM below predetermined safe thresholds. In an embodiment, the pulse rate display 1216 displays the measured pulse rate during the display of SpO2 and displays message data during the display of other parameters. For example, during the display of HbCO, the display 1216 may advantageously display the term “CO.” In an embodiment, the display of the message data may be in the same or similar color as the other displays. For example, in an embodiment, the multi-mode display 1206, the bar 1212, and the pulse display 1216 may all display data or messages in orange when the multi-mode display 1206 displays measured HbCO values.



FIG. 11 also illustrates the monitor 1200 comprising user input keys 1218, including a HbCO button 1220, mode/enter button 1222, next button 1224, power on/off button 1226, up/down button 1228, and alarm silence button 1230. In an embodiment, activation of the HbCO button 1220 toggles the measured value displayed in the multi-mode display 1206. For example, activation of the HbCO button 1220 toggles the multi-mode display 1206 from displaying measured values of SpO2 to HbCO for about ten (10) seconds. Activation of the mode/enter button 1222 or the next button 1224 during the ten (10) second period returns the multi-mode display 1206 back to SpO2. A skilled artisan will also recognize that activation of the HbCO button 1220 may advantageously toggle through a plurality of measured values, and that such values may be displayed for short segments and then return to SpO2, may remain displayed until further activation of the button 1220, or the like.


Activation of the mode/enter button 1222 cycles through various setup menus allowing a caregiver to select or activate certain entries within the menu setup system, including alarm threshold customizations, or the like. Activation of the next button 1224 can move through setup options within the menu setup system and in an embodiment is not active during normal patient monitoring. For example, a caregiver may activate the mode/enter button 1222 and the next button 1224 to specify high and low alarm thresholds for one or more of the measured parameters, to specify device sensitivity, trend settings, display customizations, color code parameters, or the like. In an embodiment, the high alarm setting for SpO2 can range from about two percent (2%) to about one hundred percent (100%) with a granularity of about one percent (1%). The low alarm setting for SpO2 can range from about one percent (1%) to about one hundred percent (100%) with a granularity of about one percent (1%). Moreover, the high alarm setting for pulse rate can range from about thirty (30) BPM to about two hundred and forty (240) BPM with a granularity of about five (5) BPM. The low alarm setting for pulse rate can range from about twenty five (25) BPM to about two hundred and thirty five (235) BPM with a granularity of about five (5) BPM. Other high and low ranges for other measured parameters will be apparent to one of ordinary skill in the art from the disclosure herein.


In a further embodiment, a caregiver may activate the mode/enter button 1222 and the next button 1224 to specify device sensitivity, such as, for example, device averaging times, probe off detection, whether to enable fast saturation calculations, or the like. Various embodiments of fast saturation calculations are disclosed in U.S. patent application Ser. No. 10/213,270, filed Aug. 5, 2002, titled “Variable Indication Estimator”. Using the menus, a caregiver may also advantageously enter appropriate information governing trend collection on one or more of the measured parameters, input signals, or the like.



FIG. 11 also shows the power on/off button 1226. Activation of the power on/off button 1226 activates and deactivates the monitor 1200. In an embodiment, press-and-hold activation for about two (2) seconds shuts the monitor 1200 off. In an additional embodiment, activation of the on/off button 1226 advantageously initiates detection of a type of attached sensor. For example, activation of the on/off button 1226 may advantageously cause the monitor 1200 to read information from a memory on an attached sensor and determine whether sufficient wavelengths exist on the sensor to determine one or more the physiological parameters discussed in the foregoing.


An artisan will recognize from the disclosure herein that the on/off button 1226 may advantageously cause an electronic determination of whether to operate in at powers consisted with the U.S. (60 Hz) or another nationality (50 Hz). In an embodiment, such automatic determination and switching is removed from the monitor 1200 in order to reduce a likelihood of problematic interfering crosstalk caused by such power switching devices.


Activation of the up/down button 1228 may advantageously adjust the volume of the pulse beep tone. Additionally, activation of the up/down button 1228 within the menu setup system, causes the selection of values with various menu options.


Moreover, activation of the alarm silence button 1230 temporarily silences audio alarms for a predetermined period, such as, for example, about one hundred and twenty (120) seconds. A second activation of the alarm silence button 1230 mutes (suspends) the alarm indefinitely, while a third activation returns the monitor 1200 to standard alarm monitoring. FIG. 11 also shows the alarm silence button 1230 includes an alarm silenced indicator 1232. The alarm silenced indicator 1232 may advantageously flash to indicate one or more alarms are temporarily silenced, may illuminate solid to indicate the alarms have been muted, or the like. Moreover, an artisan will recognize from the disclosure herein a wide variety of alarm silencing methodologies.


The monitor 1200 also includes a battery level indicator 1234 indicating remaining battery life. In the illustrated embodiment, four LED's indicate the status of the battery by incrementally deactivating to indicate proportionally decreasing battery life. In an embodiment, the four LED's may also change color as the battery charge decreases, and the final LED may begin to flash to indicate that the caregiver should replace the batteries.



FIG. 11 also shows the monitor 1200 including an audio transducer or speaker 1236. The speaker 1236 advantageously provides audible indications of alarm conditions, pulse tone and feedback for key-presses, or the like. Moreover, the monitor 1200 includes a low signal quality indicator (“SQ” or “SIQ™”) 1238. The signal IQ indicator 1238 activates to inform a caregiver that a measured value of the quality of the incoming signal is below predetermined threshold values. For example, in an embodiment, the measured value for signal IQ is at least partially based on an evaluation of the plethysmograph data's correspondence to predetermined models or characteristics of physiological signals. In an embodiment, the signal IQ indicator 1238 output may be associated with the displayed parameter. For example, the output may be associated with one threshold for the display of SpO2 and another for the display of other parameter data.


The monitor 1200 also comprises a perfusion quality index (PI™) bar 1240 (which quantifies the measure of perfusion of the patient) where in an embodiment a plurality of LED's activate from a bottom toward a top such that the bar “fills” to a level proportional to the measured value. In one embodiment, the PI™ bar 1240 shows a static value of perfusion for a given time period, such as, for example, one or more pulses. In another embodiment, or functional setting, the PI™ bar 1240 may advantageously pulse with a pulse rate, may hold the last reading and optionally fade until the next reading, may indicate historical readings through colors or fades, or the like. Additionally, the PI™ bar 1240 may advantageously change colors, flash, increasingly flash, or the like to indicate worsening measured values of perfusion.


The PI™ bar 1240 can be used to simply indicate inappropriate occlusion due, for example, to improper attachment of the sensor 1106. The PI™ bar 1240 can also be used as a diagnostic tool during low perfusion for the accurate prediction of illness severity, especially in neonates. Moreover, the rate of change in the PI™ bar 1240 can be indicative of blood loss, sleep arousal, sever hypertension, pain management, the presence or absence of drugs, or the like. According to one embodiment, the PI™ bar 1240 values may comprise a measurement of the signal strength of the arterial pulse as a percentage of the total signal received. For example, in one preferred embodiment, the alternating portion of at least one intensity signal from the sensor 1106 may advantageously be divided by the static portion of the signal. For example, an infrared intensity signal may advantageously be used as it is less subjective to noise.


In an embodiment, a measurement below about 1.25% may indicate medical situations in need of caregiver attention, specifically in monitored neonates. Because of the relevance of about 1.25%, the PI™ bar 1240 may advantageously include level indicia 1242 where the indicia 1242 swap sides of the PI™ bar 1240, thus highlighting any readings below about that threshold. Moreover, behavior of the PI™ bar 1240, as discussed above, may advantageously draw attention to monitored values below such a threshold.


As discussed above, the monitor 1200 may include output functionality that outputs, for example, trend perfusion data, such that a caregiver can monitor measured values of perfusion over time. Alternatively or additionally, the monitor 1200 may display historical trace data on an appropriate display indicating the measured values of perfusion over time. In an embodiment, the trend data is uploaded to an external computing device through, for example, the multipurpose sensor connector 1200 or other input output systems such as USB, serial or parallel ports or the like.


The monitor 1200 also includes an alarm indicator 1244 capable of providing visual queues of the status of one or more of the measured parameters. For example, the alarm indicator 1244 may advantageously be green when all of the measured parameters are within normal conditions, may gradually fade to red, may flash, increasing flash, or the like, as one or more of the measured values approaches or passes predetermined thresholds. In an embodiment, the alarm indicator 1244 activates when any parameter falls below an associated threshold, thereby advantageously informing a caregiver that perhaps a nondisplayed parameters is at an alarm condition. In another embodiment, the alarm indicator 1244 may indicate the status of the parameter displayed on the multi-mode display 1206. In an embodiment, the speaker 1236 may sound in conjunction with and/or in addition to the indicator 1244. Moreover, in an embodiment, an alarming parameter may automatically be displayed, may be emphasized, flashed, colored, combinations of the same or the like to draw a user's attention to the alarming parameter.


Although the foregoing invention has been described in terms of certain preferred embodiments, other embodiments will be apparent to those of ordinary skill in the art from the disclosure herein.



FIG. 12 illustrates an exemplary display of the patient monitor 1200. As shown in FIG. 12, the display includes the multi-mode display 1206, the pulse rate display 1216, parameter indicators 1208, 1210, the HbCO bar 1212 and indicator 1204, the PI™ bar 1240, and the alarm indicator 1244. In an embodiment, the multi-mode display 1206 and the pulse rate display 1216 each comprise a plurality of seven segment displays 1302 capable of displaying alpha-numeric information. As disclosed in the foregoing, the exemplary display may advantageously include color-coded parameter displays. Moreover, the exemplary display may include color progressions, flashing, flashing progressions, audible alarms, audible progressions, or the like, indicating worsening measured values of physiological data. In addition, in an embodiment, some or all of the displays may flash at a first rate to indicate attempts to acquire data when actual measured values are unavailable. Moreover, some or all of the display may flash at a second rate to indicate low signal quality where confidence is decreasing that the measured values reflect actual physiological conditions.



FIG. 13 illustrates the display of FIG. 12 showing measured values of SpO2, BPM, perfusion, and type of sensor, according to an exemplary embodiment of the patient monitor of FIG. 10. As shown in FIG. 13, the multi-mode display 1206 is displaying a percentage value of SpO2, and the pulse rate display 1216 is displaying a pulse rate in beats per minute. Accordingly, the parameter indicator 1210 is activated to confirm the display of measured values of SpO2. As disclosed in the foregoing, in an embodiment, the multi-mode display 1206 is red, indicating blood oxygen measurements while the pulse rate display 1216 is green, indicating normal values of a patient's pulse.



FIG. 13 also shows the PI™ bar 1240 almost fully activated, representing good perfusion. In addition, the HbCO indicator 1204 is showing communication with a sensor producing insufficient data to determine measured values of additional parameters, such as, HbCO. In an embodiment, such sensors may comprise sensors capable of emitting light at about two (2) different wavelengths, may comprise sensors with insufficient data stored on a memory associated therewith, or the like.



FIG. 14 illustrates the display of FIG. 12 showing measured values of HbCO, perfusion, and type of sensor, according to an exemplary embodiment of the patient monitor of FIG. 10. As shown in FIG. 14, the multi-mode display 1206 is displaying a percentage value of HbCO, and the pulse rate display 1216 is displaying an appropriate message indicating the HbCO measurement, such as, for example, “CO”. Also, the multi-mode display 1206 has shifted the data to the left to quickly and efficiently indicate that the displayed parameter is other than SpO2. Accordingly, the parameter indicator 1208 is also activated to confirm the display of measured values of HbCO. As disclosed in the foregoing, in an embodiment, the multi-mode display 1206 and pulse rate display message 1216 are orange.



FIG. 14 also shows the PI™ bar 1240 almost fully activated, representing good perfusion. In addition, the activation of the HbCO indicator 1204 represents communication with a sensor capable of producing sufficient data to determine measured values of HbCO. In an embodiment, such sensors may comprise sensors capable of emitting light at about eight (8) or more different wavelengths; however, such sensors may comprise about two (2) or more different wavelengths. Moreover, such sensors may have appropriate data stored on a memory associated therewith, or the like. FIG. 14 also shows the HbCO measurement being about 20% (as illustrated on the HbCO bar 1212 and multi-mode display 1206) thereby indicating a potentially dangerous situation that if exacerbated, will become quite problematic. Therefore, the alarm indicator 1244 is also activated, and in some embodiments, the speaker 1236 as well.



FIG. 15 illustrates the display of FIG. 12 showing measured values of SpO2, HbCO, BPM, perfusion, and type of sensor, according to an exemplary embodiment of the patient monitor of FIG. 10. In contrast to FIG. 13, FIG. 15 shows that the monitor 1200 is communicating with a sensor capable of producing sufficient data to determine measured values of HbCO, even though the displayed values are that of SpO2 and BPM. Thus, FIG. 15 shows the activation of the HbCO indicator 1204, and the continuous monitoring of HbCO by the HbCO bar 1212. FIG. 15 also shows a high value of HbCO, and therefore, the indication of an alarm condition by activation of the alarm indicator 1244. In an embodiment, upon determination of an alarm condition on a nondisplayed parameter, the monitor 1200 may advantageously provide an alarm indication through speaker and alarm indicator activation, automatic toggle to the nondisplayed parameter on the multi-mode display 1206 for a defined or undefined time, or the like.



FIG. 16 illustrates a top elevation view of an exemplary handheld noninvasive multi-parameter patient monitor 1700 capable of displaying at least HbCO and HbMet, such as, for example, the patient monitor of FIG. 10. Patient monitors exhibiting combinations of many of the features described herein are advantageously commercially available from Masimo under the brand name “Rad 57 cm.” As shown in FIG. 16, the monitor 1700 comprises a monitor similar to monitor 1200 disclosed with reference to FIG. 11. Moreover, monitor 1700 further includes a multi-mode display 1706 capable of displaying, for example, measurements of HbMet and BPM. In an embodiment, the display 1706 has insufficient space or display real estate to display the many parameters capable of being measured by the monitor 1700. Thus, the multi-mode display 1706 may advantageously cycle through two or more measured parameters. In such embodiments, the monitor 1700 may also advantageously include parameter indicators 1708, 1710, providing additional visual queues as to which parameter is currently displayed. In an embodiment, the display 1706 may also cycle colors, flash rates, or other audio or visual queues providing readily identifiable information as to which measured parameter is displayed. For example, when the multi-mode display 1706 displays measured values of BPM that are normal, the numbers may advantageously appear in green, while normal measured values of HbMet may appear in blue. Moreover, in an embodiment, the display 1706 may flash at a predefined rate when searching for saturation and at another predefined rate when a signal quality is below a predetermined threshold.



FIG. 16 also illustrates the monitor 1700 comprising user input keys 1718, including an HbCO/HbMet button 1220. In an embodiment, activation of the HbCO/HbMet button 1720 toggles the measured value displayed in the multi-mode display 1706. For example, activation of the HbCO/HbMet button 1720 toggles the multi-mode display 1206 from displaying measured values of SpO2 and BPM, to HbCO and HbMet for about ten (10) seconds. Activation of the mode/enter button 1222 or the next button 1224 during the ten (10) second period returns the multi-mode display 1706 back to SpO2 and BPM. A skilled artisan will also recognize that activation of the HbCO/HbMet button 1720 may advantageously toggle through a plurality of measured values, and that such values may be displayed for short segments and then return to SpO2 and BPM, may remain displayed until further activation of the button 1720, or the like.


The monitor 1700 also comprises a coarser indication of HbMet through an HbMet bar 1740. In an embodiment, a plurality of LED's activate from a bottom toward a top such that the bar “fills” to a level proportional to the measured value, with increments at about 0.5%, about 1%, about 2%, about 3%, about 4%, about 5%, about 7.5%, about 10%, about 15% and greater than about 20%, although an artisan will recognize from the disclosure herein other useful delineations. Additionally, the HbMet bar 1740 may advantageously change colors, flash, increasingly flash, or the like to indicate worsening measured values of perfusion.


Although disclosed with reference to the HbMet bar 1740, and artisan will recognize from the disclosure herein other coarse or even gross indications of HbMet, or any measured parameter. For example, a single LED may advantageously show green, yellow, and red, to indicate worsening coarse values of HbMet. Alternatively, a single LED may simply light to indicate an alarm or approaching alarm condition.



FIG. 17 illustrates an exemplary display of the patient monitor 1700 of FIG. 16. As shown in FIG. 17, the display includes the multi-mode displays 1206, 1706, parameter indicators 1208, 1210, 1708, 1710, the HbCO bar 1212 and indicator 1204, the HbMet bar 1740, and the alarm indicator 1244. In an embodiment, the multi-mode display 1706 is similar to multi-mode display 1206, comprising a plurality of seven segment displays 1302 capable of displaying alpha-numeric information, and capable of altering its display characteristics or aspects in a wide variety of configurations discussed with reference to the display 1206.



FIG. 18 illustrates the display of FIG. 17 showing measured values of SpO2, BPM, HbCO, HbMet, and type of sensor according to an exemplary embodiment of the patient monitor of FIG. 10. FIG. 18 also shows the HbMet bar 1740 near the bottom and corresponding to about 1%, representing acceptable HbMet, while the HbCO bar 1212 hovers at a dangerous near 20%. In addition, the HbCO indicator 1204 is showing communication with a sensor producing sufficient data to determine measured values of additional parameters, such as, HbMet, HbCO or the like. In an embodiment, such sensors may comprise sensors capable of emitting light of more than two (2) different wavelengths, preferably more than four (4) different wavelengths, and more preferably eight (8) or more different wavelengths.



FIG. 19 illustrates the display of FIG. 17 showing measured values of HbCO, HbMet, and type of sensor according to an exemplary embodiment of the patient monitor of FIG. 10. As shown in FIG. 19, the multi-mode display 1706 is displaying a percentage value of HbMet that is shifted using the parameter indicator 1708. The data has been advantageously shifted to the left to quickly and efficiently indicate that the displayed parameter is other than BPM. Accordingly, the parameter indicator 1708 is also activated to confirm the display of measured values of HbMet. As disclosed in the foregoing, in an embodiment, the multi-mode display 1706 is blue.



FIG. 19 also shows the HbMet bar 1740 nearly empty, representing acceptable HbMet. In addition, the activation of the HbCO indicator 1204 represents communication with a sensor capable of producing sufficient data to determine measured values of HbCO. In an embodiment, such sensors may have appropriate data stored on a memory associated therewith, or the like. FIG. 19 also shows the HbCO measurement being about 20% (as illustrated on the HbCO bar 1212 and multi-mode display 1206) thereby indicating a potentially dangerous situation that if exacerbated, will become quite problematic. Therefore, the alarm indicator 1244 is also activated, and in some embodiments, the speaker 1236 as well.



FIG. 20A illustrates a perspective view of an exemplary noninvasive multi-parameter patient monitor 2000, such as, for example, the patient monitor of FIG. 10. Moreover, FIGS. 20B-20E illustrate exemplary display screens of the patient monitor of FIG. 20A. As shown in FIGS. 20A-20B, an embodiment of the monitor 2000 includes a display 2001 showing a plurality of parameter data. For example, the display may advantageously comprise a CRT or an LCD display including circuitry similar to that available on oximeters commercially available from Masimo Corporation of Irvine, Calif. sold under the name Radical, and disclosed in the U.S. patents referenced above. However, an artisan will recognize from the disclosure herein many commercially available display components capable of displaying multiple parameter data along with the ability to display graphical data such as plethysmographs, trend traces, and the like.


In an embodiment, the display includes a measured value of SpO2 2002, a measured value of pulse rate 2004 in BPM, a plethysmograph 2006, a measured value of HbCO 2008, a measured value of HbMet 2010, a measured value of a perfusion quality 2012, a measured value of Hbt 2014, and a derived value of fractional saturation “SpaO22016. In an embodiment, SpaO2 comprises HbO2 expressed as a percentage of the four main hemoglobin species, i.e., HbO2, Hb, HbCO, and HbMet.


In an embodiment, one or more of the foregoing parameter includes trending or prediction indicators showing the current trend or prediction for that corresponding parameter. In an embodiment, the indicators may advantageously comprise an up arrow, a down arrow, and a hyphen bar to indicate up trending/prediction, down trending/prediction, or neutral trending/prediction.



FIG. 20C illustrates an exemplary display screen showing trend graph 2040 including trend line 2042 for HbMet. In an embodiment, the trend line 2042 may be advantageously colored for quick straightforward recognition of the trending parameter, may be associated with any one or more of the foregoing alarm attributes, may include trending lines for other parameters, or the like. The display screen also shows trending directional indicators 2042, 2044 for many of the displayed physiological parameters. In an embodiment, the directional indicators 2042, 2044 may advantageously comprises arrows showing the recent trend, predicted trend, user-customizable trend, combinations thereof, or the like for the associated parameters. In an embodiment, the directional indicators 2042, 2044 comprises an up arrow indicating a rising trend/predicted trend, a middle bar indicating a somewhat stable trend/predicted trend, and a down arrow indicating a lowering trend/predicted trend. An artisan will recognize a wide variety of other directional indicators 2042, 2044 from the disclosure herein.



FIG. 20D shows an exemplary display screen in vertical format. Such vertical format could be user actuated or based on a gravity switch. FIGS. 20E-20F illustrate additional displays of various physiological parameters similar to those discussed in the foregoing. being As shown in FIG. 20G, the display includes a measured value of SpO2 2062, a measured value of pulse rate 2064 in BPM, a plethysmograph 2066, a HbCO bar 2068, and a HbMet bar 2070. In an embodiment, the HbCO bar 2068 and HbMet bar 2070 may advantageously behave the same or similarly to the HbCO bar 1212 and HbMet bar 1740. Moreover, similar bars may advantageously display any of the physiological parameters discussed herein using display indicia appropriate to that parameter. For example, a SpO2 or SpaO2 bar may advantageously range from about 0% to about 100%, and more preferably range from about 50% to about 100%, while a Hbt bar may advantageously range from about 0 to about 30.


Moreover, similar to the disclosure above, the measured value of SpO2 2062 may advantageously toggle to measured values of HbCO, HbMet, Hbt, or the like based on, for example, actuation of user input keys, or the like.


In addition to the foregoing, the display may also include graphical data showing one or more color-coded or other identifying indicia for traces of trend data. Moreover, other graphical presentations may advantageously provide readily identifiable indications of monitored parameters or combinations of monitored parameters of the patient. For example, in an embodiment, the display includes a SpaO2 graph 2072. The SpaO2 graph 2072 plots SpO2 as a function of other blood analytes (1-SpaO2), where SpaO2 comprises HbO2 expressed as a percentage of the four main hemoglobin species, i.e., HbO2, Hb, HbCO, and HbMet. Thus, as shown in FIG. 20C, as the slope of the displayed line or arrow increases, the caregiver can readily note that the majority of hemoglobin carriers are being used to carry oxygen, and not, for example, harmful carbon monoxide. On the other hand, as the slope decreases, the caregiver can readily and advantageously note that the number of hemoglobin species available to carry oxygen is decreasing, regardless of the current value of SpO2. Moreover, the length of the arrow or line also provides an indication of wellness, e.g., the higher the line the more oxygen saturation, the lower the line, the more likely there may be desaturation event, or the like.


Thus, the SpaO2 graph 2072 provides the caregiver with the ability to recognize that even though the measured value of SpO2 may be within acceptable ranges, there are potentially an unacceptable number of hemoglobin carriers unavailable for carrying oxygen, and that other potential problems may exist, such as, for example, harmful carbon monoxide levels, or the like. In an embodiment, various alarm conditions may cause the graph 2072 to change color, flash, or any combination of alarm indications discussed in the forgoing. Moreover, FIG. 20G illustrates yet an additional display of the foregoing parameters.


An embodiment may also include the monitor 2000 advantageously defining regions of wellness/severity of the monitored patient. For example, because the graph 2072 comprises two dimensions, the monitor 2000 may advantageously define regions where the patient's measured physiological parameters are considered acceptable, regions where the patient is considered at risk, regions where the patient is critical, and the like. For example, one region of acceptability may include a high SpO2 and a low 1-SpaO2, another region of risk may include a high SpO2 and a high 1-SpaO2, and another critical region may include a low SpO2 and a high 1-SpaO2. Moreover, an artisan will recognize from the disclosure herein that different parameters may also be combined to provide readily identifiable indications of patient wellness.


In addition to or as an alternative to the two dimensional SpaO2 graph 2072, the monitor 2000 may also include a three dimensional graph, such as, for example, extending the graph 2072 along the variable of time. In this embodiment, the forgoing regions advantageously become three dimensional surfaces of wellness. Moreover, trend data may also be advantageously added to the surface to provide a history of when particular monitored parameters dipped in and out of various surfaces of wellness, risk, criticality, or the like. Such trend data could be color-coded, text identified, or the like. An artisan will also recognize that such surfaces may be dynamic. For example, measurements of HbCO>about 5 may dictate that trend data showing SpO2<about 90% should be considered critical; however, measurements of HbCO<about 5 may dictate only SpO2<about 85% would be critical. Again, an artisan will recognize from the disclosure herein other parameter combinations to create a wide variety of wellness/critical regions or surfaces that provide readily available visual or audio indications of patient well being, trigger specific alarms, or the like.


Moreover, the monitor 2000 may advantageously employ enlargement or reorganization of parameter data based on, for example, the severity of the measurement. For example, the monitor 2000 may display values for HbCO in a small portion of the screen or in the background, and when HbCO begins to approach abnormal levels, the small portion may advantageously grown as severity increases, even in some embodiments to dominate the display. Such visual alarming can be combined with audio alarms such as announcements, alarms, rising frequencies, or the like, and other visual alarms such as flashing, coloration, or the like to assist a caregiver in noticing the increasing severity of a monitored parameter. In an embodiment, a location of the display of an alarming value is changed to be displayed in a larger display area, such as 2002, so as to be readily noticeable and its display values readily ascertainable.


Although the foregoing invention has been described in terms of certain preferred embodiments, other embodiments will be apparent to those of ordinary skill in the art from the disclosure herein. For example, the monitor 1102 may advantageously be adapted to monitor or be included in a monitor capable of measuring physiological parameters other than those determined through absorption spectroscopy, such as, for example, blood pressure, ECG, EKG, respiratory rates, volumes, inputs for blood pressure sensors, acoustical sensors, and the like. Moreover, the monitor 1102 may be adapted for wireless communication to and from the sensor 1106, and/or to and from other monitoring devices, such as, for example, multi-parameter or legacy monitoring devices.

Claims
  • 1. A noninvasive monitor configured to communicate with a sensor that includes an emitter and one or more detectors, the sensor configured to position the emitter and the one or more detectors proximate to tissue of a patient, the noninvasive monitor comprising: an input configured to receive, from the sensor, a signal that is responsive to detected light from the emitter attenuated by the tissue; andone or more hardware processors configured to process the signal to determine measurement values for a physiological parameter of the patient; anda display configured to present a gauge panel, the gauge panel configured to present a plurality of indicators responsive to the measurement values, the gauge panel comprising: a numerical indicator of the plurality of indicators comprising a numerical readout, the numerical readout being configured to equal one of the measurement values,a gauge face extending from a first side of the numerical readout to a second side of the numerical readout, a plurality of positions along the gauge face being mapped to different parameter values for the physiological parameter ranging from a low parameter value to a high parameter value,a gauge indicator of the plurality of indicators being overlaid on the gauge face, the gauge indicator being located at a position of the plurality of positions that maps to the one of the measurement values, anda graphical histogram indicator disposed along the gauge face and comprising a plurality of bars.
  • 2. The noninvasive monitor of claim 1, wherein a first bar of the plurality of bars corresponds to a first range of the parameter values and has a first height responsive to an amount of time that the gauge indicator indicated a first portion of the gauge indicator that maps to the first range, and a second bar of the plurality of bars corresponds to a second range of the parameter values different from the first range and has a second height responsive to an amount of time that the gauge indicator indicated a second portion of the gauge indicator different from the first portion that maps to the second range, the first bar being located proximate to the first portion and the second bar being located proximate to the second portion.
  • 3. The noninvasive monitor of claim 1, wherein in response to a user selection of an area covered by the graphical histogram indicator, the graphical histogram indicator is visually replaced on the gauge panel with a slider configured to receive a user input indicating an input value, the input value being between the low parameter value and the high parameter value.
  • 4. The noninvasive monitor of claim 1, wherein in response to a user selection of an area covered by the graphical histogram indicator, the graphical histogram indicator is visually replaced on the gauge panel with a slider configured to receive a plurality of user inputs indicating a first input value and a second input value, the first input value and the second input value being between the low parameter value and the high parameter value.
  • 5. The noninvasive monitor of claim 4, wherein the one or more hardware processors is configured to set a first alarm threshold to the first input value and a second alarm threshold to the second input value.
  • 6. The noninvasive monitor of claim 4, wherein the slider is a dual knob slider.
  • 7. The noninvasive monitor of claim 1, wherein an alarm limit value is overlaid on the graphical histogram indicator, the alarm limit value identifying an alarm threshold for the measurement values.
  • 8. The noninvasive monitor of claim 1, wherein a plurality of alarm limit values are overlaid on the graphical histogram indicator, the plurality of alarm limit values identifying a plurality of alarm thresholds for the measurement values.
  • 9. The noninvasive monitor of claim 1, wherein the graphical histogram indicator comprises a plurality of bins that have the same length, the plurality of bins having lighter coloring than the plurality of bars and being positioned behind the plurality of bars.
  • 10. The noninvasive monitor of claim 1, wherein the gauge face is formed as an arc that has a raised center, wherein the plurality of bars are disposed along the arc.
  • 11. The noninvasive monitor of claim 1, wherein the gauge face is formed as a half circle, wherein the plurality of bars are disposed along the half circle.
  • 12. The noninvasive monitor of claim 1, wherein the gauge face comprises an alarm bar extending from an end of the gauge face, the alarm bar defining an alarm region for the measurement values.
  • 13. The noninvasive monitor of claim 1, wherein the physiological parameter comprises total hemoglobin.
  • 14. The noninvasive monitor of claim 1, wherein the physiological parameter comprises methemoglobin.
  • 15. The noninvasive monitor of claim 1, wherein the gauge panel comprises a parameter type indicator that indicates one of total hemoglobin, methemoglobin, and oxygen saturation.
  • 16. The noninvasive monitor of claim 1, wherein a degree to which the gauge indicator is displaced from a vertical position indicates a degree of abnormality of the one of the measurement values.
  • 17. The noninvasive monitor of claim 1, wherein the gauge face is disposed between the graphical histogram indicator and the numerical indicator.
  • 18. The noninvasive monitor of claim 1, wherein the gauge face comprises an edge that causes the gauge face to appear three dimensional.
CROSS-REFERENCE TO RELATED APPLICATIONS

The present application is a continuation of U.S. patent application Ser. No. 13/663,457, filed Oct. 29, 2012, titled Physiological Monitor Gauge Panel, which claims priority benefit under 35 U.S.C. § 119(e) to U.S. Provisional Patent Application Ser. No. 61/552,427, filed Oct. 27, 2011, titled Physiological Monitor Gauge Panel; the above-cited applications hereby incorporated in their entirety by reference herein.

US Referenced Citations (968)
Number Name Date Kind
4300548 Jones Nov 1981 A
4960128 Gordon et al. Oct 1990 A
4964408 Hink et al. Oct 1990 A
5041187 Hink et al. Aug 1991 A
5069213 Polczynski Dec 1991 A
5163438 Gordon et al. Nov 1992 A
5319355 Russek Jun 1994 A
5337744 Branigan Aug 1994 A
5341805 Stavridi et al. Aug 1994 A
D353195 Savage et al. Dec 1994 S
D353196 Savage et al. Dec 1994 S
5377676 Vari et al. Jan 1995 A
D359546 Savage et al. Jun 1995 S
5431170 Mathews Jul 1995 A
D361840 Savage et al. Aug 1995 S
D362063 Savage et al. Sep 1995 S
5452717 Branigan et al. Sep 1995 A
D363120 Savage et al. Oct 1995 S
5456252 Vari et al. Oct 1995 A
5479934 Imran Jan 1996 A
5482036 Diab et al. Jan 1996 A
5490505 Diab et al. Feb 1996 A
5494043 O'Sullivan et al. Feb 1996 A
5533511 Kaspari et al. Jul 1996 A
5534851 Russek Jul 1996 A
5561275 Savage et al. Oct 1996 A
5562002 Lalin Oct 1996 A
5590649 Caro et al. Jan 1997 A
5602924 Durand et al. Feb 1997 A
5632272 Diab et al. May 1997 A
5638816 Kiani-Azarbayjany et al. Jun 1997 A
5638818 Diab et al. Jun 1997 A
5645440 Tobler et al. Jul 1997 A
5685299 Diab et al. Nov 1997 A
D393830 Tobler et al. Apr 1998 S
5743262 Lepper, Jr. et al. Apr 1998 A
5758644 Diab et al. Jun 1998 A
5760910 Lepper, Jr. et al. Jun 1998 A
5769785 Diab et al. Jun 1998 A
5782757 Diab et al. Jul 1998 A
5785659 Caro et al. Jul 1998 A
5791347 Flaherty et al. Aug 1998 A
5810734 Caro et al. Sep 1998 A
5823950 Diab et al. Oct 1998 A
5830131 Caro et al. Nov 1998 A
5833618 Caro et al. Nov 1998 A
5860919 Kiani-Azarbayjany et al. Jan 1999 A
5890929 Mills et al. Apr 1999 A
5904654 Wohltmann et al. May 1999 A
5919134 Diab Jul 1999 A
5934925 Tobler et al. Aug 1999 A
5940182 Lepper, Jr. et al. Aug 1999 A
5987343 Kinast Nov 1999 A
5995855 Kiani et al. Nov 1999 A
5997343 Mills et al. Dec 1999 A
6002952 Diab et al. Dec 1999 A
6011986 Diab et al. Jan 2000 A
6027452 Flaherty et al. Feb 2000 A
6036642 Diab et al. Mar 2000 A
6045509 Caro et al. Apr 2000 A
6067462 Diab et al. May 2000 A
6081735 Diab et al. Jun 2000 A
6088607 Diab et al. Jul 2000 A
6110522 Lepper, Jr. et al. Aug 2000 A
6124597 Shehada Sep 2000 A
6128521 Marro et al. Oct 2000 A
6129675 Jay Oct 2000 A
6144868 Parker Nov 2000 A
6151516 Kiani-Azarbayjany et al. Nov 2000 A
6152754 Gerhardt et al. Nov 2000 A
6157850 Diab et al. Dec 2000 A
6165005 Mills et al. Dec 2000 A
6184521 Coffin, IV et al. Feb 2001 B1
6206830 Diab et al. Mar 2001 B1
6229856 Diab et al. May 2001 B1
6232609 Snyder et al. May 2001 B1
6236872 Diab et al. May 2001 B1
6241683 Macklem et al. Jun 2001 B1
6253097 Aronow et al. Jun 2001 B1
6256523 Diab et al. Jul 2001 B1
6263222 Diab et al. Jul 2001 B1
6278522 Lepper, Jr. et al. Aug 2001 B1
6280213 Tobler et al. Aug 2001 B1
6285896 Tobler et al. Sep 2001 B1
6301493 Marro et al. Oct 2001 B1
6308089 von der Ruhr et al. Oct 2001 B1
6317627 Ennen et al. Nov 2001 B1
6321100 Parker Nov 2001 B1
6325761 Jay Dec 2001 B1
6334065 Al-Ali et al. Dec 2001 B1
6343224 Parker Jan 2002 B1
6349228 Kiani et al. Feb 2002 B1
6360114 Diab et al. Mar 2002 B1
6368283 Xu et al. Apr 2002 B1
6371921 Caro et al. Apr 2002 B1
6377829 Al-Ali Apr 2002 B1
6388240 Schulz et al. May 2002 B2
6397091 Diab et al. May 2002 B2
6430437 Marro Aug 2002 B1
6430525 Weber et al. Aug 2002 B1
6463311 Diab Oct 2002 B1
6470199 Kopotic et al. Oct 2002 B1
6501975 Diab et al. Dec 2002 B2
6505059 Kollias et al. Jan 2003 B1
6515273 Al-Ali Feb 2003 B2
6519487 Parker Feb 2003 B1
6525386 Mills et al. Feb 2003 B1
6526300 Kiani et al. Feb 2003 B1
6541756 Schulz et al. Apr 2003 B2
6542764 Al-Ali et al. Apr 2003 B1
6580086 Schulz et al. Jun 2003 B1
6584336 Ali et al. Jun 2003 B1
6595316 Cybulski et al. Jul 2003 B2
6597932 Tian et al. Jul 2003 B2
6597933 Kiani et al. Jul 2003 B2
6606511 Ali et al. Aug 2003 B1
6632181 Flaherty et al. Oct 2003 B2
6639668 Trepagnier Oct 2003 B1
6640116 Diab Oct 2003 B2
6643530 Diab et al. Nov 2003 B2
6650917 Diab et al. Nov 2003 B2
6654624 Diab et al. Nov 2003 B2
6658276 Kiani et al. Dec 2003 B2
6661161 Lanzo et al. Dec 2003 B1
6671531 Al-Ali et al. Dec 2003 B2
6678543 Diab et al. Jan 2004 B2
6684090 Ali et al. Jan 2004 B2
6684091 Parker Jan 2004 B2
6697656 Al-Ali Feb 2004 B1
6697657 Shehada et al. Feb 2004 B1
6697658 Al-Ali Feb 2004 B2
RE38476 Diab et al. Mar 2004 E
6699194 Diab et al. Mar 2004 B1
6714804 Al-Ali et al. Mar 2004 B2
RE38492 Diab et al. Apr 2004 E
6721582 Trepagnier et al. Apr 2004 B2
6721585 Parker Apr 2004 B1
6725075 Al-Ali Apr 2004 B2
6728560 Kollias et al. Apr 2004 B2
6735459 Parker May 2004 B2
6745060 Diab et al. Jun 2004 B2
6760607 Al-Ali Jul 2004 B2
6770028 Ali et al. Aug 2004 B1
6771994 Kiani et al. Aug 2004 B2
6792300 Diab et al. Sep 2004 B1
6813511 Diab et al. Nov 2004 B2
6816741 Diab Nov 2004 B2
6822564 Al-Ali Nov 2004 B2
6826419 Diab et al. Nov 2004 B2
6830711 Mills et al. Dec 2004 B2
6850787 Weber et al. Feb 2005 B2
6850788 Al-Ali Feb 2005 B2
6852083 Caro et al. Feb 2005 B2
6861639 Al-Ali Mar 2005 B2
6898452 Al-Ali et al. May 2005 B2
6920345 Al-Ali et al. Jul 2005 B2
6931268 Kiani-Azarbayjany et al. Aug 2005 B1
6934570 Kiani et al. Aug 2005 B2
6939305 Flaherty et al. Sep 2005 B2
6943348 Coffin, IV Sep 2005 B1
6950687 Al-Ali Sep 2005 B2
6961598 Diab Nov 2005 B2
6970792 Diab Nov 2005 B1
6979812 Al-Ali Dec 2005 B2
6985764 Mason et al. Jan 2006 B2
6993371 Kiani et al. Jan 2006 B2
6996427 Ali et al. Feb 2006 B2
6999904 Weber et al. Feb 2006 B2
7003338 Weber et al. Feb 2006 B2
7003339 Diab et al. Feb 2006 B2
7015451 Dalke et al. Mar 2006 B2
7024233 Ali et al. Apr 2006 B2
7027849 Al-Ali Apr 2006 B2
7030749 Al-Ali Apr 2006 B2
7039449 Al-Ali May 2006 B2
7041060 Flaherty et al. May 2006 B2
7044918 Diab May 2006 B2
7048687 Reuss et al. May 2006 B1
7067893 Mills et al. Jun 2006 B2
7096052 Mason et al. Aug 2006 B2
7096054 Abdul-Hafiz et al. Aug 2006 B2
7132641 Schulz et al. Nov 2006 B2
7142901 Kiani et al. Nov 2006 B2
7149561 Diab Dec 2006 B2
7186966 Al-Ali Mar 2007 B2
7190261 Al-Ali Mar 2007 B2
7215984 Diab May 2007 B2
7215986 Diab May 2007 B2
7221971 Diab May 2007 B2
7225006 Al-Ali et al. May 2007 B2
7225007 Al-Ali May 2007 B2
RE39672 Shehada et al. Jun 2007 E
7239905 Kiani-Azarbayjany et al. Jul 2007 B2
7245953 Parker Jul 2007 B1
7254429 Schurman et al. Aug 2007 B2
7254431 Al-Ali Aug 2007 B2
7254433 Diab et al. Aug 2007 B2
7254434 Schulz et al. Aug 2007 B2
7272425 Al-Ali Sep 2007 B2
7274955 Kiani et al. Sep 2007 B2
D554263 Al-Ali Oct 2007 S
7280858 Al-Ali et al. Oct 2007 B2
7289835 Mansfield et al. Oct 2007 B2
7292883 De Felice et al. Nov 2007 B2
7295866 Al-Ali Nov 2007 B2
7328053 Diab et al. Feb 2008 B1
7332784 Mills et al. Feb 2008 B2
7340287 Mason et al. Mar 2008 B2
7341559 Schulz et al. Mar 2008 B2
7343186 Lamego et al. Mar 2008 B2
D566282 Al-Ali et al. Apr 2008 S
7355512 Al-Ali Apr 2008 B1
7356365 Schurman Apr 2008 B2
7371981 Abdul-Hafiz May 2008 B2
7373193 Al-Ali et al. May 2008 B2
7373194 Weber et al. May 2008 B2
7376453 Diab et al. May 2008 B1
7377794 Al Ali et al. May 2008 B2
7377899 Weber et al. May 2008 B2
7383070 Diab et al. Jun 2008 B2
7415297 Al-Ali et al. Aug 2008 B2
7428432 Ali et al. Sep 2008 B2
7438683 Al-Ali et al. Oct 2008 B2
7440787 Diab Oct 2008 B2
7454240 Diab et al. Nov 2008 B2
7467002 Weber et al. Dec 2008 B2
7469157 Diab et al. Dec 2008 B2
7471969 Diab et al. Dec 2008 B2
7471971 Diab et al. Dec 2008 B2
7483729 Al-Ali et al. Jan 2009 B2
7483730 Diab et al. Jan 2009 B2
7489958 Diab et al. Feb 2009 B2
7496391 Diab et al. Feb 2009 B2
7496393 Diab et al. Feb 2009 B2
D587657 Al-Ali et al. Mar 2009 S
7499741 Diab et al. Mar 2009 B2
7499835 Weber et al. Mar 2009 B2
7500950 Al-Ali et al. Mar 2009 B2
7509154 Diab et al. Mar 2009 B2
7509494 Al-Ali Mar 2009 B2
7510849 Schurman et al. Mar 2009 B2
7526328 Diab et al. Apr 2009 B2
7530942 Diab May 2009 B1
7530949 Al Ali et al. May 2009 B2
7530955 Diab et al. May 2009 B2
7563110 Al-Ali et al. Jul 2009 B2
7596398 Al-Ali et al. Sep 2009 B2
7618375 Flaherty Nov 2009 B2
D606659 Kiani et al. Dec 2009 S
7647083 Al-Ali et al. Jan 2010 B2
D609193 Al-Ali et al. Feb 2010 S
D614305 Al-Ali et al. Apr 2010 S
RE41317 Parker May 2010 E
7729733 Al-Ali et al. Jun 2010 B2
7734320 Al-Ali Jun 2010 B2
7761127 Al-Ali et al. Jul 2010 B2
7761128 Al-Ali et al. Jul 2010 B2
7764982 Dalke et al. Jul 2010 B2
D621516 Kiani et al. Aug 2010 S
7791155 Diab Sep 2010 B2
7801581 Diab Sep 2010 B2
7822452 Schurman et al. Oct 2010 B2
RE41912 Parker Nov 2010 E
7844313 Kiani et al. Nov 2010 B2
7844314 Al-Ali Nov 2010 B2
7844315 Al-Ali Nov 2010 B2
7865222 Weber et al. Jan 2011 B2
7873497 Weber et al. Jan 2011 B2
7880606 Al-Ali Feb 2011 B2
7880626 Al-Ali et al. Feb 2011 B2
7891355 Al-Ali et al. Feb 2011 B2
7894868 Al-Ali et al. Feb 2011 B2
7899507 Al-Ali et al. Mar 2011 B2
7899518 Trepagnier et al. Mar 2011 B2
7904132 Weber et al. Mar 2011 B2
7909772 Popov et al. Mar 2011 B2
7910875 Al-Ali Mar 2011 B2
7919713 Al-Ali et al. Apr 2011 B2
7937128 Al-Ali May 2011 B2
7937129 Mason et al. May 2011 B2
7937130 Diab et al. May 2011 B2
7941199 Kiani May 2011 B2
7951086 Flaherty et al. May 2011 B2
7957780 Lamego et al. Jun 2011 B2
7962188 Kiani et al. Jun 2011 B2
7962190 Diab et al. Jun 2011 B1
7976472 Kiani Jul 2011 B2
7988637 Diab Aug 2011 B2
7990382 Kiani Aug 2011 B2
7991446 Al-Ali et al. Aug 2011 B2
8000761 Al-Ali Aug 2011 B2
8008088 Bellott et al. Aug 2011 B2
RE42753 Kiani-Azarbayjany Sep 2011 E
8019400 Diab et al. Sep 2011 B2
8028701 Al-Ali et al. Oct 2011 B2
8029765 Bellott et al. Oct 2011 B2
8036727 Schurman et al. Oct 2011 B2
8036728 Diab et al. Oct 2011 B2
8046040 Ali et al. Oct 2011 B2
8046041 Diab et al. Oct 2011 B2
8046042 Diab et al. Oct 2011 B2
8048040 Kiani Nov 2011 B2
8050728 Al-Ali et al. Nov 2011 B2
8092379 Baker, Jr. Jan 2012 B2
RE43169 Parker Feb 2012 E
8118620 Al-Ali et al. Feb 2012 B2
8126528 Diab et al. Feb 2012 B2
8128572 Diab et al. Mar 2012 B2
8130105 Al-Ali et al. Mar 2012 B2
8145287 Diab et al. Mar 2012 B2
8150487 Diab et al. Apr 2012 B2
8175672 Parker May 2012 B2
8180420 Diab et al. May 2012 B2
8182443 Kiani May 2012 B1
8185180 Diab et al. May 2012 B2
8190223 Al-Ali et al. May 2012 B2
8190227 Diab et al. May 2012 B2
8203438 Kiani et al. Jun 2012 B2
8203704 Merritt et al. Jun 2012 B2
8204566 Schurman et al. Jun 2012 B2
8219172 Schurman et al. Jul 2012 B2
8224411 Al-Ali et al. Jul 2012 B2
8228181 Al-Ali Jul 2012 B2
8229533 Diab et al. Jul 2012 B2
8233955 Al-Ali et al. Jul 2012 B2
8244325 Al-Ali et al. Aug 2012 B2
8251903 LeBoeuf Aug 2012 B2
8255026 Al-Ali Aug 2012 B1
8255027 Al-Ali et al. Aug 2012 B2
8255028 Al-Ali et al. Aug 2012 B2
8260577 Weber et al. Sep 2012 B2
8265723 McHale et al. Sep 2012 B1
8274360 Sampath et al. Sep 2012 B2
8280473 Al-Ali Oct 2012 B2
8290559 Shariati Oct 2012 B2
8301217 Al-Ali et al. Oct 2012 B2
8306596 Schurman et al. Nov 2012 B2
8310336 Muhsin et al. Nov 2012 B2
8315683 Al-Ali et al. Nov 2012 B2
RE43860 Parker Dec 2012 E
8337403 Al-Ali et al. Dec 2012 B2
8346330 Lamego Jan 2013 B2
8353842 Al-Ali et al. Jan 2013 B2
8355766 MacNeish, III et al. Jan 2013 B2
8359080 Diab et al. Jan 2013 B2
8364223 Al-Ali et al. Jan 2013 B2
8364226 Diab et al. Jan 2013 B2
8374665 Lamego Feb 2013 B2
8385995 Al-ali et al. Feb 2013 B2
8385996 Smith et al. Feb 2013 B2
8388353 Kiani et al. Mar 2013 B2
8399822 Al-Ali Mar 2013 B2
8401602 Kiani Mar 2013 B2
8405608 Al-Ali et al. Mar 2013 B2
8414499 Al-Ali et al. Apr 2013 B2
8418524 Al-Ali Apr 2013 B2
8423106 Lamego et al. Apr 2013 B2
8428967 Olsen et al. Apr 2013 B2
8430817 Al-Ali et al. Apr 2013 B1
8437825 Dalvi et al. May 2013 B2
8455290 Siskavich Jun 2013 B2
8457703 Al-Ali Jun 2013 B2
8457707 Kiani Jun 2013 B2
8463349 Diab et al. Jun 2013 B2
8466286 Bellot et al. Jun 2013 B2
8471713 Poeze et al. Jun 2013 B2
8473020 Kiani et al. Jun 2013 B2
8483787 Al-Ali et al. Jul 2013 B2
8489364 Weber et al. Jul 2013 B2
8498684 Weber et al. Jul 2013 B2
8504128 Blank et al. Aug 2013 B2
8509867 Workman et al. Aug 2013 B2
8515509 Bruinsma et al. Aug 2013 B2
8523781 Al-Ali Sep 2013 B2
8529301 Al-Ali et al. Sep 2013 B2
8532727 Ali et al. Sep 2013 B2
8532728 Diab et al. Sep 2013 B2
D692145 Al-Ali et al. Oct 2013 S
8547209 Kiani et al. Oct 2013 B2
8548548 Al-Ali Oct 2013 B2
8548549 Schurman et al. Oct 2013 B2
8548550 Al-Ali et al. Oct 2013 B2
8560032 Al-Ali et al. Oct 2013 B2
8560034 Diab et al. Oct 2013 B1
8570167 Al-Ali Oct 2013 B2
8570503 Vo et al. Oct 2013 B2
8571617 Reichgott et al. Oct 2013 B2
8571618 Lamego et al. Oct 2013 B1
8571619 Al-Ali et al. Oct 2013 B2
8584345 Al-Ali et al. Oct 2013 B2
8577431 Lamego et al. Nov 2013 B2
8581732 Al-Ali et al. Nov 2013 B2
8588880 Abdul-Hafiz et al. Nov 2013 B2
8600467 Al-Ali et al. Dec 2013 B2
8606342 Diab Dec 2013 B2
8626255 Al-Ali et al. Jan 2014 B2
8630691 Lamego et al. Jan 2014 B2
8634889 Al-Ali et al. Jan 2014 B2
8641631 Sierra et al. Feb 2014 B2
8652060 Al-Ali Feb 2014 B2
8663107 Kiani Mar 2014 B2
8666468 Al-Ali Mar 2014 B1
8667967 Al-Ali et al. Mar 2014 B2
8670811 O'Reilly Mar 2014 B2
8670814 Diab et al. Mar 2014 B2
8676286 Weber et al. Mar 2014 B2
8682407 Al-Ali Mar 2014 B2
RE44823 Parker Apr 2014 E
RE44875 Kiani et al. Apr 2014 E
8690799 Telfort et al. Apr 2014 B2
8700112 Kiani Apr 2014 B2
8702627 Telfort et al. Apr 2014 B2
8706179 Parker Apr 2014 B2
8712494 MacNeish, III et al. Apr 2014 B1
8715206 Telfort et al. May 2014 B2
8718735 Lamego et al. May 2014 B2
8718737 Diab et al. May 2014 B2
8718738 Blank et al. May 2014 B2
8720249 Al-Ali May 2014 B2
8721541 Al-Ali et al. May 2014 B2
8721542 Al-Ali et al. May 2014 B2
8723677 Kiani May 2014 B1
8740792 Kiani et al. Jun 2014 B1
8754776 Poeze et al. Jun 2014 B2
8755535 Telfort et al. Jun 2014 B2
8755856 Diab et al. Jun 2014 B2
8755872 Marinow Jun 2014 B1
8761850 Lamego Jun 2014 B2
8764671 Kiani Jul 2014 B2
8768423 Shakespeare et al. Jul 2014 B2
8771204 Telfort et al. Jul 2014 B2
8777634 Kiani et al. Jul 2014 B2
8781543 Diab et al. Jul 2014 B2
8781544 Al-Ali et al. Jul 2014 B2
8781549 Al-Ali et al. Jul 2014 B2
8788003 Schurman et al. Jul 2014 B2
8790268 Al-Ali Jul 2014 B2
8801613 Al-Ali et al. Aug 2014 B2
8821397 Al-Ali et al. Sep 2014 B2
8821415 Al-Ali et al. Sep 2014 B2
8830449 Lamego et al. Sep 2014 B1
8831700 Schurman et al. Sep 2014 B2
8840549 Al-Ali et al. Sep 2014 B2
8847740 Kiani et al. Sep 2014 B2
8849365 Smith et al. Sep 2014 B2
8852094 Al-Ali et al. Oct 2014 B2
8852994 Wojtczuk et al. Oct 2014 B2
8868147 Stippick et al. Oct 2014 B2
8868150 Al-Ali et al. Oct 2014 B2
8870792 Al-Ali et al. Oct 2014 B2
8886271 Kiani et al. Nov 2014 B2
8888539 Al-Ali et al. Nov 2014 B2
8888708 Diab et al. Nov 2014 B2
8892180 Weber et al. Nov 2014 B2
8897847 Al-Ali Nov 2014 B2
8909310 Lamego et al. Dec 2014 B2
8911377 Al-Ali Dec 2014 B2
8912909 Al-Ali et al. Dec 2014 B2
8920317 Al-Ali et al. Dec 2014 B2
8921699 Al-Ali et al. Dec 2014 B2
8922382 Al-Ali et al. Dec 2014 B2
8929964 Al-Ali et al. Jan 2015 B2
8942777 Diab et al. Jan 2015 B2
8948834 Diab et al. Feb 2015 B2
8948835 Diab Feb 2015 B2
8961415 LeBoeuf Feb 2015 B2
8965471 Lamego Feb 2015 B2
8983564 Al-Ali Mar 2015 B2
8989831 Al-Ali et al. Mar 2015 B2
8996085 Kiani et al. Mar 2015 B2
8998809 Kiani Apr 2015 B2
9028429 Telfort et al. May 2015 B2
9037207 Al-Ali et al. May 2015 B2
9060721 Reichgott et al. Jun 2015 B2
9066666 Kiani Jun 2015 B2
9066680 Al-Ali et al. Jun 2015 B1
9072474 Al-Ali et al. Jul 2015 B2
9078560 Schurman et al. Jul 2015 B2
9084569 Weber et al. Jul 2015 B2
9095316 Welch et al. Aug 2015 B2
9106038 Telfort et al. Aug 2015 B2
9107625 Telfort et al. Aug 2015 B2
9107626 Al-Ali et al. Aug 2015 B2
9113831 Al-Ali Aug 2015 B2
9113832 Al-Ali Aug 2015 B2
9119595 Lamego Sep 2015 B2
9131881 Diab et al. Sep 2015 B2
9131882 Al-Ali et al. Sep 2015 B2
9131883 Al-Ali Sep 2015 B2
9131917 Telfort et al. Sep 2015 B2
9138180 Coverston et al. Sep 2015 B1
9138182 Al-Ali et al. Sep 2015 B2
9138192 Weber et al. Sep 2015 B2
9142117 Muhsin et al. Sep 2015 B2
9153112 Kiani et al. Oct 2015 B1
9153121 Kiani et al. Oct 2015 B2
9161696 Al-Ali et al. Oct 2015 B2
9161713 Al-Ali et al. Oct 2015 B2
9167995 Lamego et al. Oct 2015 B2
9176141 Al-Ali et al. Nov 2015 B2
9186102 Bruinsma et al. Nov 2015 B2
9192312 Al-Ali Nov 2015 B2
9192329 Al-Ali Nov 2015 B2
9192351 Telfort et al. Nov 2015 B1
9195385 Al-Ali et al. Nov 2015 B2
9211072 Kiani Dec 2015 B2
9211095 Al-Ali Dec 2015 B1
9218454 Kiani et al. Dec 2015 B2
9220409 Lisogurski Dec 2015 B2
9226696 Kiani Jan 2016 B2
9241662 Al-Ali et al. Jan 2016 B2
9245668 Vo et al. Jan 2016 B1
9259185 Abdul-Hafiz et al. Feb 2016 B2
9267572 Barker et al. Feb 2016 B2
9277880 Poeze et al. Mar 2016 B2
9289167 Diab et al. Mar 2016 B2
9295421 Kiani et al. Mar 2016 B2
9307928 Al-Ali et al. Apr 2016 B1
9323894 Kiani Apr 2016 B2
D755392 Hwang et al. May 2016 S
9326712 Kiani May 2016 B1
9333316 Kiani May 2016 B2
9339220 Lamego et al. May 2016 B2
9341565 Lamego et al. May 2016 B2
9351673 Diab et al. May 2016 B2
9351675 Al-Ali et al. May 2016 B2
9364181 Kiani et al. Jun 2016 B2
9368671 Wojtczuk et al. Jun 2016 B2
9370325 Al-Ali et al. Jun 2016 B2
9370326 McHale et al. Jun 2016 B2
9370335 Al-Ali et al. Jun 2016 B2
9375185 Ali et al. Jun 2016 B2
9386953 Al-Ali Jul 2016 B2
9386961 Al-Ali et al. Jul 2016 B2
9392945 Al-Ali et al. Jul 2016 B2
9397448 Al-Ali et al. Jul 2016 B2
9408542 Kinast et al. Aug 2016 B1
9436645 Al-Ali et al. Sep 2016 B2
9445759 Lamego et al. Sep 2016 B1
9466919 Kiani et al. Oct 2016 B2
9474474 Lamego et al. Oct 2016 B2
9480422 Al-Ali Nov 2016 B2
9480435 Olsen Nov 2016 B2
9492110 Al-Ali et al. Nov 2016 B2
9510779 Poeze et al. Dec 2016 B2
9517024 Kiani et al. Dec 2016 B2
9532722 Lamego et al. Jan 2017 B2
9538949 Al-Ali et al. Jan 2017 B2
9538980 Telfort et al. Jan 2017 B2
9549696 Lamego et al. Jan 2017 B2
9554737 Schurman et al. Jan 2017 B2
9560996 Kiani Feb 2017 B2
9560998 Al-Ali et al. Feb 2017 B2
9566019 Al-Ali et al. Feb 2017 B2
9579039 Jansen et al. Feb 2017 B2
9591975 Dalvi et al. Mar 2017 B2
9622692 Lamego et al. Apr 2017 B2
9622693 Diab Apr 2017 B2
D788312 Al-Ali et al. May 2017 S
9636055 Al-Ali et al. May 2017 B2
9636056 Al-Ali May 2017 B2
9649054 Lamego et al. May 2017 B2
9662052 Al-Ali et al. May 2017 B2
9668679 Schurman et al. Jun 2017 B2
9668680 Bruinsma et al. Jun 2017 B2
9668703 Al-Ali Jun 2017 B2
9675286 Diab Jun 2017 B2
9687160 Kiani Jun 2017 B2
9693719 Al-Ali et al. Jul 2017 B2
9693737 Al-Ali Jul 2017 B2
9697928 Al-Ali et al. Jul 2017 B2
9717425 Kiani et al. Aug 2017 B2
9717458 Lamego et al. Aug 2017 B2
9724016 Al-Ali et al. Aug 2017 B1
9724024 Al-Ali Aug 2017 B2
9724025 Kiani et al. Aug 2017 B1
9730640 Diab et al. Aug 2017 B2
9743887 Al-Ali et al. Aug 2017 B2
9749232 Sampath et al. Aug 2017 B2
9750442 Olsen Sep 2017 B2
9750443 Smith et al. Sep 2017 B2
9750461 Telfort Sep 2017 B1
9775545 Al-Ali et al. Oct 2017 B2
9775546 Diab et al. Oct 2017 B2
9775570 Al-Ali Oct 2017 B2
9778079 Al-Ali et al. Oct 2017 B1
9782077 Lamego et al. Oct 2017 B2
9782110 Kiani Oct 2017 B2
9787568 Lamego et al. Oct 2017 B2
9788735 Al-Ali Oct 2017 B2
9788768 Al-Ali et al. Oct 2017 B2
9795300 Al-Ali Oct 2017 B2
9795310 Al-Ali Oct 2017 B2
9795358 Telfort et al. Oct 2017 B2
9795739 Al-Ali et al. Oct 2017 B2
9801556 Kiani Oct 2017 B2
9801588 Weber et al. Oct 2017 B2
9808188 Perea et al. Nov 2017 B1
9814418 Weber et al. Nov 2017 B2
9820691 Kiani Nov 2017 B2
9833152 Kiani et al. Dec 2017 B2
9833180 Shakespeare et al. Dec 2017 B2
9839379 Al-Ali et al. Dec 2017 B2
9839381 Weber et al. Dec 2017 B1
9847002 Kiani et al. Dec 2017 B2
9847749 Kiani et al. Dec 2017 B2
9848800 Lee et al. Dec 2017 B1
9848806 Al-Ali et al. Dec 2017 B2
9848807 Lamego Dec 2017 B2
9861298 Eckerbom et al. Jan 2018 B2
9861304 Al-Ali et al. Jan 2018 B2
9861305 Weber et al. Jan 2018 B1
9867578 Al-Ali et al. Jan 2018 B2
9872623 Al-Ali Jan 2018 B2
9876320 Coverston et al. Jan 2018 B2
9877650 Muhsin et al. Jan 2018 B2
9877686 Al-Ali et al. Jan 2018 B2
9891079 Dalvi Feb 2018 B2
9895107 Al-Ali et al. Feb 2018 B2
9913617 Al-Ali et al. Mar 2018 B2
9924893 Schurman et al. Mar 2018 B2
9924897 Abdul-Hafiz Mar 2018 B1
9936917 Poeze et al. Apr 2018 B2
9943269 Muhsin et al. Apr 2018 B2
9949676 Al-Ali Apr 2018 B2
9955937 Telfort May 2018 B2
9965946 Al-Ali May 2018 B2
9980667 Kiani et al. May 2018 B2
D820865 Muhsin et al. Jun 2018 S
9986919 Lamego et al. Jun 2018 B2
9986952 Dalvi et al. Jun 2018 B2
9989560 Poeze et al. Jun 2018 B2
9993207 Al-Ali et al. Jun 2018 B2
10007758 Al-Ali et al. Jun 2018 B2
D822215 Al-Ali et al. Jul 2018 S
D822216 Barker et al. Jul 2018 S
10010276 Al-Ali et al. Jul 2018 B2
10032002 Kiani et al. Jul 2018 B2
10039482 Al-Ali et al. Aug 2018 B2
10052037 Kinast et al. Aug 2018 B2
10058275 Al-Ali et al. Aug 2018 B2
10064562 Al-Ali Sep 2018 B2
10076282 LeBoeuf Sep 2018 B2
10086138 Novak, Jr. Oct 2018 B1
10092200 Al-Ali et al. Oct 2018 B2
10092249 Kiani et al. Oct 2018 B2
10098550 Al-Ali et al. Oct 2018 B2
10098591 Al-Ali et al. Oct 2018 B2
10098610 Al-Ali et al. Oct 2018 B2
10366787 Sampath Jul 2019 B2
10456038 Lamego Oct 2019 B2
10503379 Al-Ali Dec 2019 B2
10729402 Al-Ali Aug 2020 B2
20060074321 Kouchi et al. Apr 2006 A1
20060161054 Reuss et al. Jul 2006 A1
20070043269 Mannheimer Feb 2007 A1
20070282478 Al-Ali et al. Dec 2007 A1
20080146892 LeBoeuf Jun 2008 A1
20090043446 Drew et al. Feb 2009 A1
20090046096 Rampersad Feb 2009 A1
20090054743 Stewart Feb 2009 A1
20090171167 Baker, Jr. Jul 2009 A1
20090247984 Lamego et al. Oct 2009 A1
20090259114 Johnson Oct 2009 A1
20090275813 Davis Nov 2009 A1
20090275844 Al-Ali Nov 2009 A1
20100004518 Vo et al. Jan 2010 A1
20100004519 Lamego Jan 2010 A1
20100030040 Poeze et al. Feb 2010 A1
20100261979 Kiani Oct 2010 A1
20110001605 Kiani et al. Jan 2011 A1
20110082711 Poeze et al. Apr 2011 A1
20110087083 Poeze et al. Apr 2011 A1
20110105854 Kiani et al. May 2011 A1
20110125060 Telfort et al. May 2011 A1
20110208015 Welch et al. Aug 2011 A1
20110213212 Al-Ali Sep 2011 A1
20110227927 Garmon et al. Sep 2011 A1
20110230733 Al-Ali Sep 2011 A1
20110237911 Lamego et al. Sep 2011 A1
20110237969 Eckerbom et al. Sep 2011 A1
20110288383 Diab Nov 2011 A1
20120041316 Al-Ali et al. Feb 2012 A1
20120046557 Kiani Feb 2012 A1
20120059267 Lamego et al. Mar 2012 A1
20120088984 Al-Ali et al. Apr 2012 A1
20120116175 Al-Ali et al. May 2012 A1
20120165629 Merritt et al. Jun 2012 A1
20120179006 Jansen et al. Jul 2012 A1
20120209082 Al-Ali Aug 2012 A1
20120209084 Olsen et al. Aug 2012 A1
20120226117 Lamego Sep 2012 A1
20120227739 Kiani Sep 2012 A1
20120283524 Kiani et al. Nov 2012 A1
20120296178 Lamego et al. Nov 2012 A1
20120319816 Al-Ali Dec 2012 A1
20120330112 Lamego et al. Dec 2012 A1
20130023775 Lamego et al. Jan 2013 A1
20130045685 Kiani Feb 2013 A1
20130046204 Lamego et al. Feb 2013 A1
20130041591 Lamego Mar 2013 A1
20130060147 Welch et al. Mar 2013 A1
20130096405 Garfio Apr 2013 A1
20130096936 Sampath et al. Apr 2013 A1
20130109935 Al-Ali et al. May 2013 A1
20130162433 Muhsin et al. Jun 2013 A1
20130190581 Al-Ali et al. Jul 2013 A1
20130197328 Diab et al. Aug 2013 A1
20130211214 Olsen Aug 2013 A1
20130243021 Siskavich Sep 2013 A1
20130253334 Al-Ali et al. Sep 2013 A1
20130254717 Al-Ali Sep 2013 A1
20130262730 Al-Ali et al. Oct 2013 A1
20130267804 Al-Ali Oct 2013 A1
20130274571 Diab et al. Oct 2013 A1
20130274572 Al-Ali et al. Oct 2013 A1
20130296672 O'Neil et al. Nov 2013 A1
20130296713 Al-Ali et al. Nov 2013 A1
20130317370 Dalvi et al. Nov 2013 A1
20130324808 Al-Ali et al. Dec 2013 A1
20130331660 Al-Ali et al. Dec 2013 A1
20130331670 Kiani Dec 2013 A1
20130338461 Lamego et al. Dec 2013 A1
20140012100 Al-Ali et al. Jan 2014 A1
20140025306 Weber et al. Jan 2014 A1
20140034353 Al-Ali et al. Feb 2014 A1
20140051953 Lamego et al. Feb 2014 A1
20140058230 Abdul-Hafiz et al. Feb 2014 A1
20140066783 Kiani et al. Mar 2014 A1
20140077956 Sampath et al. Mar 2014 A1
20140081100 Muhsin et al. Mar 2014 A1
20140081175 Telfort Mar 2014 A1
20140094667 Schurman et al. Apr 2014 A1
20140100434 Diab et al. Apr 2014 A1
20140114199 Lamego et al. Apr 2014 A1
20140120564 Workman et al. May 2014 A1
20140121482 Merritt et al. May 2014 A1
20140121483 Kiani May 2014 A1
20140127137 Bellott et al. May 2014 A1
20140128696 Al-Ali May 2014 A1
20140128699 Al-Ali et al. May 2014 A1
20140129702 Lamego et al. May 2014 A1
20140135588 Al-Ali et al. May 2014 A1
20140142401 Al-Ali et al. May 2014 A1
20140142402 Al-Ali et al. May 2014 A1
20140163344 Al-Ali Jun 2014 A1
20140163402 Lamego et al. Jun 2014 A1
20140166076 Kiani et al. Jun 2014 A1
20140171763 Diab Jun 2014 A1
20140180038 Kiani Jun 2014 A1
20140180154 Sierra et al. Jun 2014 A1
20140180160 Brown et al. Jun 2014 A1
20140187973 Brown et al. Jul 2014 A1
20140194709 Al-Ali et al. Jul 2014 A1
20140194711 Al-Ali Jul 2014 A1
20140194766 Al-Ali et al. Jul 2014 A1
20140206963 Al-Ali Jul 2014 A1
20140213864 Abdul-Hafiz et al. Jul 2014 A1
20140243627 Diab et al. Aug 2014 A1
20140266790 Al-Ali et al. Sep 2014 A1
20140275808 Poeze et al. Sep 2014 A1
20140275835 Lamego et al. Sep 2014 A1
20140275871 Lamego et al. Sep 2014 A1
20140275872 Merritt et al. Sep 2014 A1
20140275881 Lamego et al. Sep 2014 A1
20140276115 Dalvi et al. Sep 2014 A1
20140288400 Diab et al. Sep 2014 A1
20140296664 Bruinsma et al. Oct 2014 A1
20140303520 Telfort et al. Oct 2014 A1
20140309506 Lamego et al. Oct 2014 A1
20140316217 Purdon et al. Oct 2014 A1
20140316218 Purdon et al. Oct 2014 A1
20140316228 Blank et al. Oct 2014 A1
20140323825 Al-Ali et al. Oct 2014 A1
20140323897 Brown et al. Oct 2014 A1
20140323898 Purdon et al. Oct 2014 A1
20140330092 Al-Ali et al. Nov 2014 A1
20140330098 Merritt et al. Nov 2014 A1
20140330099 Al-Ali et al. Nov 2014 A1
20140333440 Kiani Nov 2014 A1
20140336481 Shakespeare et al. Nov 2014 A1
20140343436 Kiani Nov 2014 A1
20140357966 Al-Ali et al. Dec 2014 A1
20140371548 Al-Ali et al. Dec 2014 A1
20140378784 Kiani et al. Dec 2014 A1
20150005600 Blank et al. Jan 2015 A1
20150011907 Purdon et al. Jan 2015 A1
20150012231 Poeze et al. Jan 2015 A1
20150018650 Al-Ali et al. Jan 2015 A1
20150025406 Al-Ali Jan 2015 A1
20150032029 Al-Ali et al. Jan 2015 A1
20150038859 Dalvi et al. Feb 2015 A1
20150045637 Dalvi Feb 2015 A1
20150051462 Olsen Feb 2015 A1
20150080754 Purdon et al. Mar 2015 A1
20150087936 Al-Ali et al. Mar 2015 A1
20150094546 Al-Ali Apr 2015 A1
20150097701 Al-Ali et al. Apr 2015 A1
20150099950 Al-Ali et al. Apr 2015 A1
20150099951 Al-Ali et al. Apr 2015 A1
20150099955 Al-Ali et al. Apr 2015 A1
20150101844 Al-Ali et al. Apr 2015 A1
20150106121 Muhsin et al. Apr 2015 A1
20150112151 Muhsin et al. Apr 2015 A1
20150116076 Al-Ali et al. Apr 2015 A1
20150126830 Schurman et al. May 2015 A1
20150133755 Smith et al. May 2015 A1
20150141781 Weber et al. May 2015 A1
20150165312 Kiani Jun 2015 A1
20150196237 Lamego Jul 2015 A1
20150196249 Brown et al. Jul 2015 A1
20150201874 Diab Jul 2015 A1
20150208966 Al-Ali Jul 2015 A1
20150216459 Al-Ali et al. Aug 2015 A1
20150230755 Al-Ali et al. Aug 2015 A1
20150238722 Al-Ali Aug 2015 A1
20150245773 Lamego et al. Sep 2015 A1
20150245794 Al-Ali Sep 2015 A1
20150257689 Al-Ali et al. Sep 2015 A1
20150272514 Kiani et al. Oct 2015 A1
20150351697 Weber et al. Dec 2015 A1
20150351704 Kiani et al. Dec 2015 A1
20150359429 Al-Ali et al. Dec 2015 A1
20150366472 Kiani Dec 2015 A1
20150366507 Blank Dec 2015 A1
20150374298 Al-Ali et al. Dec 2015 A1
20150380875 Coverston et al. Dec 2015 A1
20160000362 Diab et al. Jan 2016 A1
20160007930 Weber et al. Jan 2016 A1
20160029932 Al-Ali Feb 2016 A1
20160029933 Al-Ali et al. Feb 2016 A1
20160045118 Kiani Feb 2016 A1
20160051205 Al-Ali et al. Feb 2016 A1
20160058338 Schurman et al. Mar 2016 A1
20160058347 Reichgott et al. Mar 2016 A1
20160066823 Kind et al. Mar 2016 A1
20160066824 Al-Ali et al. Mar 2016 A1
20160066879 Telfort et al. Mar 2016 A1
20160072429 Kiani et al. Mar 2016 A1
20160081552 Wojtczuk et al. Mar 2016 A1
20160095543 Telfort et al. Apr 2016 A1
20160095548 Al-Ali et al. Apr 2016 A1
20160103598 Al-Ali et al. Apr 2016 A1
20160113527 Al-Ali et al. Apr 2016 A1
20160143548 Al-Ali May 2016 A1
20160166182 Al-Ali et al. Jun 2016 A1
20160166183 Poeze et al. Jun 2016 A1
20160166188 Bruinsma et al. Jun 2016 A1
20160166210 Al-Ali Jun 2016 A1
20160192869 Kiani et al. Jul 2016 A1
20160196388 Lamego Jul 2016 A1
20160197436 Barker et al. Jul 2016 A1
20160213281 Eckerbom et al. Jul 2016 A1
20160228043 O'Neil et al. Aug 2016 A1
20160233632 Scruggs et al. Aug 2016 A1
20160234944 Schmidt et al. Aug 2016 A1
20160270735 Diab et al. Sep 2016 A1
20160283665 Sampath et al. Sep 2016 A1
20160287090 Al-Ali et al. Oct 2016 A1
20160287786 Kiani Oct 2016 A1
20160296169 McHale et al. Oct 2016 A1
20160310052 Al-Ali et al. Oct 2016 A1
20160314260 Kiani Oct 2016 A1
20160324486 Al-Ali et al. Nov 2016 A1
20160324488 Olsen Nov 2016 A1
20160327984 Al-Ali et al. Nov 2016 A1
20160328528 Al-Ali et al. Nov 2016 A1
20160331332 Al-Ali Nov 2016 A1
20160367173 Dalvi et al. Dec 2016 A1
20170007134 Al-Ali et al. Jan 2017 A1
20170007190 Al-Ali et al. Jan 2017 A1
20170007198 Al-Ali et al. Jan 2017 A1
20170014083 Diab et al. Jan 2017 A1
20170014084 Al-Ali et al. Jan 2017 A1
20170021099 Al-Ali et al. Jan 2017 A1
20170027456 Kinast et al. Feb 2017 A1
20170042488 Muhsin Feb 2017 A1
20170055851 Al-Ali Mar 2017 A1
20170055882 Al-Ali et al. Mar 2017 A1
20170055887 Al-Ali Mar 2017 A1
20170055896 Al-Ali et al. Mar 2017 A1
20170079594 Telfort et al. Mar 2017 A1
20170086723 Al-Ali et al. Mar 2017 A1
20170143281 Olsen May 2017 A1
20170147774 Kiani May 2017 A1
20170156620 Al-Ali et al. Jun 2017 A1
20170173632 Al-Ali Jun 2017 A1
20170187146 Kiani et al. Jun 2017 A1
20170188919 Al-Ali et al. Jul 2017 A1
20170196464 Jansen et al. Jul 2017 A1
20170196470 Lamego et al. Jul 2017 A1
20170202490 Al-Ali et al. Jul 2017 A1
20170224262 Al-Ali Aug 2017 A1
20170228516 Sampath et al. Aug 2017 A1
20170245790 Al-Ali et al. Aug 2017 A1
20170251974 Shreim et al. Sep 2017 A1
20170251975 Shreim et al. Sep 2017 A1
20170258403 Abdul-Hafiz et al. Sep 2017 A1
20170311851 Schurman et al. Nov 2017 A1
20170311891 Kiani et al. Nov 2017 A1
20170325728 Al-Ali et al. Nov 2017 A1
20170332976 Al-Ali et al. Nov 2017 A1
20170340293 Al-Ali et al. Nov 2017 A1
20170360310 Kiani et al. Dec 2017 A1
20170367632 Al-Ali et al. Dec 2017 A1
20180008146 Al-Ali et al. Jan 2018 A1
20180014752 Al-Ali et al. Jan 2018 A1
20180028124 Al-Ali et al. Feb 2018 A1
20180055385 Al-Ali Mar 2018 A1
20180055390 Kiani et al. Mar 2018 A1
20180055430 Diab et al. Mar 2018 A1
20180064381 Shakespeare et al. Mar 2018 A1
20180069776 Lamego et al. Mar 2018 A1
20180070867 Smith et al. Mar 2018 A1
20180082767 Al-Ali et al. Mar 2018 A1
20180085068 Telfort Mar 2018 A1
20180087937 Al-Ali et al. Mar 2018 A1
20180103874 Lee et al. Apr 2018 A1
20180103905 Kiani Apr 2018 A1
20180110478 Al-Ali Apr 2018 A1
20180116575 Perea et al. May 2018 A1
20180125368 Lamego et al. May 2018 A1
20180125430 Al-Ali et al. May 2018 A1
20180125445 Telfort et al. May 2018 A1
20180130325 Kiani et al. May 2018 A1
20180132769 Weber et al. May 2018 A1
20180132770 Lamego May 2018 A1
20180146901 Al-Ali et al. May 2018 A1
20180146902 Kiani et al. May 2018 A1
20180153442 Eckerbom et al. Jun 2018 A1
20180153446 Kiani Jun 2018 A1
20180153447 Al-Ali et al. Jun 2018 A1
20180153448 Weber et al. Jun 2018 A1
20180161499 Al-Ali et al. Jun 2018 A1
20180168491 Al-Ali et al. Jun 2018 A1
20180174679 Sampath et al. Jun 2018 A1
20180174680 Sampath et al. Jun 2018 A1
20180182484 Sampath et al. Jun 2018 A1
20180184917 Kiani Jul 2018 A1
20180192953 Shreim et al. Jul 2018 A1
20180192955 Al-Ali et al. Jul 2018 A1
20180199871 Pauley et al. Jul 2018 A1
20180206795 Al-Ali Jul 2018 A1
20180206815 Telfort Jul 2018 A1
20180213583 Al-Ali Jul 2018 A1
20180214031 Kiani et al. Aug 2018 A1
20180214090 Al-Ali et al. Aug 2018 A1
20180218792 Muhsin et al. Aug 2018 A1
20180225960 Al-Ali et al. Aug 2018 A1
20180238718 Dalvi Aug 2018 A1
20180242853 Al-Ali Aug 2018 A1
20180242921 Muhsin et al. Aug 2018 A1
20180242926 Muhsin et al. Aug 2018 A1
20180247353 Al-Ali et al. Aug 2018 A1
20180247712 Muhsin et al. Aug 2018 A1
20180249933 Schurman et al. Sep 2018 A1
20180253947 Muhsin et al. Sep 2018 A1
20180256087 Al-Ali et al. Sep 2018 A1
20180256113 Weber et al. Sep 2018 A1
20180285094 Housel et al. Oct 2018 A1
20180289325 Poeze et al. Oct 2018 A1
20180289337 Al-Ali et al. Oct 2018 A1
20180296161 Shreim et al. Oct 2018 A1
20180300919 Muhsin et al. Oct 2018 A1
20180310822 Indorf et al. Nov 2018 A1
20180310823 Al-Ali et al. Nov 2018 A1
20190029578 Al-Ali Jan 2019 A1
20190142283 Lamego May 2019 A1
Non-Patent Literature Citations (5)
Entry
US 8,845,543 B2, 09/2014, Diab et al. (withdrawn)
MVP-50P Overview, http://web.archive.org/web/20090422043625/http://www.buy-ei.com/Pages/MVP/MVP-50P_Overview.html, archived Apr. 22, 2009.
BMI Scale, “How to Translate BMI into Pounds: Finally, a Body Mass Index Calculator for the Rest of Us”, http://web.archive.org/web/20080620122802/http://www.prweb.com/releases/2005/07/prweb262133.htm, archived on Jun. 20, 2008.
MVP-50P Instrument Marking Requirements for Certified Aircraft, http://web.archive.org/web/20090306210759/http://www.buy-ei.com/Information/Redlines_Limits_MVP.pdf, archived on Mar. 6, 2009.
Excel Univariate, http://web.archive.org/web/20090228103558/http://cameron.econ.ucdavis.edu/excel/exl lhistogram.html, archived on Feb. 29, 2009.
Related Publications (1)
Number Date Country
20180087937 A1 Mar 2018 US
Provisional Applications (1)
Number Date Country
61552427 Oct 2011 US
Continuations (1)
Number Date Country
Parent 13663457 Oct 2012 US
Child 15719218 US